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Nitric Oxide And Interleukin 8 Production By The Human Colon
Summary
The aetiology of inflammatory bowel disease is unknown. Previous work has 
shown that nitric oxide (NO) is produced in high concentrations in the human 
colon when inflammation is present in ulcerative colitis, and that NO 
concentrations diminish when the inflammation resolves. The enzyme 
responsible for this is believed to be the inducible form of nitric oxide synthase 
(iNOS). In human colonic mucosa iNOS expression is limited to epithelial cells 
and previous work on colonic epithelial cell lines e.g. HT-29 cells demonstrates 
that expression can be induced by stimulation using a mixture of pro- 
inflammatory cytokines (IL-1, TNF-a and IFN-y). Expression can be modulated 
by the T-cell derived cytokines IL-4 and IL-13 but is not affected by IL-10 
despite the evidence that IL-10 has some effect in clinical practice.
The work described in this thesis shows that two steroids, prednisolone and 
budesonide, commonly used in the treatment of colitis have no effect on either 
NO or interleukin-8  production by stimulated HT-29 cells in clinically relevant 
doses. Further work on colonic biopsies from patients with newly diagnosed 
colitis showed that they produced NO and IL-8  in large quantities and that this 
could be inhibited with small concentrations of either prednisolone or 
budesonide. iNOS and IL-8  mRNA expression in these biopsies were measured 
using a semi-quantitative polymerase chain reaction (PCR) technique which 
showed a significant fall in levels when the biopsies were treated with either 
steroid. Work on the effect of the three T-cell derived cytokines on the colonic 
biopsies showed that the production of both NO and IL-8  was easily inhibited by 
both IL-4 and IL-10. Expression of iNOS and IL-8  mRNA was also inhibited by 
IL-4 and IL-10. The effect of IL-13 was much less pronounced.
Colonic biopsies from histologically normal colon in patients with and without 
colitis were stimulated with the same pro-inflammatory cytokine mix that was 
used on the HT-29 cells. A significant increase in NO production and IL-8  levels 
and a rise in iNOS mRNA and IL-8  mRNA was demonstrated. Increased IL-8 
expression was inhibited by the T cell derived cytokines in histologically normal 
biopsies from patients with or without colitis but NO production and iNOS 
mRNA expression was only inhibited in histologically normal biopsies from 
patients with colitis.
To examine further why colonic biopsies and HT-29 cells respond differently to 
T-cell derived cytokines and steroids with respect to NO and IL-8  production, the 
effect of these substances was studied in a co-culture of peripheral blood mixed 
mononuclear cells (MMCs) and HT-29 cells. The co-culture produced large 
quantities of NO when stimulated with IFN-y and lipopolysaccharide (LPS), but 
there was no effect on NO production in the HT-29 cells or MMCs when 
cultured alone. Conditioned media from the LPS and IFN-y treated MMCs 
induced NO production in HT-29 cells, demonstrating that the MMCs produced a 
soluble factor or factors that stimulate NO production in the HT-29 cells. This 
effect was inhibited by treatment of the HT-29 cells with IL-1 receptor antagonist 
or by treatment of the MMCs with prednisolone or budesonide or all of the T cell 
derived cytokines including IL-10. The inflammatory responses of epithelial cells 
in intact colonic mucosa appear to be largely determined by their interaction with 
other cell populations within the mucosa such as MMCs.
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1.1 Inflammatory Bowel Disease
1.1.1 Historical perspective
There are two idiopathic inflammatory bowel diseases (IBD): Ulcerative Colitis 
(UC) and Crohn’s Disease (CD). Although originally thought to be two ends of a 
spectrum of a single disease, it has become clear that they are two different 
diseases and thus should be considered separately. Both CD and UC are thought 
by some to be 20th Century diseases, however, they were probably originally 
described some time before this.
Morson’s review of Matthew Baillies 1793 Morbid Anatomy o f Some o f the Most 
Important Parts o f the Human Body shows that patients were dying from 
ulcerating conditions of the colon during the later part of the 18th Century 
(Morson, 1970). Crohn’s disease was probably described as long ago as 1813 by 
Combe and Saunders who described a case of stricturing of the lower part of the 
ileum as far as the colon that was “constricted for the space of three feet to the 
size of a turkey quill” (Combe and Saunders, 1813). In 1828 Abercrombie 
reported some further cases of a regional ileitis (Abercrombie, 1828). In 1889 a 
further patient with what would probably become known as Crohn’s Disease was 
described by Fenwick in a series of lectures given in London (Fenwick, 1889). 
Ulcerative Colitis was probably first described in 1859 by Samuel Wilks, a 
physician at Guy's Hospital, who recognised that “simple, idiopathic colitis”; 
could be distinguished from other forms of colitis, such as bacterial dysentery.
2This original case concerned a 42 year old woman who died after several months 
of diarrhoea and fever. An autopsy demonstrated a transmural inflammation of the 
colon thought to be unlike other infectious causes known at the time (Wilks, 
1859). By 1907 over 300 patients with inflammatory changes of the bowel had 
been reported in a survey of seven London hospitals. Nearly one-half of the 
patients died from perforation of the colon with peritonitis (Cameron and 
Rippman, 1909). In 1907 the increased incidence of colonic carcinoma in those 
patients with ulcerative colitis was recognised by Lockhart-Mummery (Lockhart- 
Mummery, 1907). Speculation as to the cause of colitis began to increase and in 
1921 Hurst implicated an organism “related to B. dysenteriae” (Hurst, 1921). A 
daily treatment regimen of the colon with dilute solutions of silver nitrate or 
tannic acid and the intravenous administration of an anti-dysenteric serum was 
tried with little effect.
Further descriptions of what in future would be known as Crohn’s disease, was 
described by Dalziel in 1913 in the British Medical Journal. This description was 
of a condition causing a chronic interstitial enteritis (Dalziel, 1913). Crohn 
described a detailed description of several cases of regional ileitis in a series of 
articles from 1932 (Crohn et al., 1932;Crohn, 1934;Crohn, 1949)
Between 1930 and 1950s sulphanilamide and penicillin were tried with increasing 
success. A major breakthrough came with the use of ACTH and adrenal steroids 
which were introduced for treatment in 1950. In 1951 the complete reversibility 
of ulcerative colitis was demonstrated in a group of patients who responded to 
steroid therapy (Kirsner et a l, 1951). Because of this success with steroids, recent 
developments in therapeutics and searches for aetiologies of IBD have 
concentrated upon the premise that IBD is an inflammatory condition rather than
having an infective aetiology. Although the overall prognosis of ulcerative colitis 
and Crohn's disease has improved over the years, a cure has still not been found. 
Until the causes of these diseases have been clearly identified, therapeutic 
strategies for these conditions continues to be based on interrupting the 
immunological mechanisms involved and inhibiting the gut inflammation.
1.1.2. Pathological features of IBD
The inflammation in UC is superficial, that is, it is limited to the mucosa and 
submucosa, and is confined to the large bowel. It affects the rectum and a variable 
length of the colon proximally. Histologically, the disease is characterised by an 
infiltration of both acute and chronic inflammatory cells in the lamina propria and 
the crypts which form microabscesses. The deeper layers of the intestinal wall are 
characteristically not involved.
In contrast, CD is a transmural inflammation that may occur anywhere throughout 
the alimentary tract from the mouth to the anus. The disease can affect the deeper 
layers of the bowel wall producing superficial and deep ulceration and can also 
leading to collagen deposition and fibrosis. The presence of granulomata is a 
characteristic feature of Crohn’s disease.
Both diseases are characterised by a chronic relapsing course and associated with 
many extra-intestinal manifestations. Increasing evidence suggests that the two 
conditions are distinct although they share important common pathological 
mechanisms. It seems apparent that the tissue injury seems to be mediated by the 
immune system, although whether this is the initiating event or a secondary event 
is unclear. It is likely that the aetiology of IBD is not a single cause and probably 
represents an interaction between various factors both host and environmental. In
4the following section, recent clues in aetiology and pathogeneses of IBD are 
reviewed, concentrating mostly on immunological mechanisms.
1.2 Aetiological Factors in IBD
Although it seems likely that different external aetiological factors act upon a 
genetically susceptible individual, this is by no means proven. A number of 
genetic influences, especially immunological abnormalities (host), dietary and 
infectious agents (environmental) have been suggested. These are discussed in 
more detail below.
1.2 .1.Genetics.
The importance of genetic factors is suggested by clustering of cases within 
families and an association amongst different racial and ethnic groups. The 
frequency of IBD in first-degree relatives varies between studies but can be as 
high as 40% (Farmer and Michener, 1986). Patients with CD have a stronger 
family history than patients with UC although there is also a strong possibility of 
patients with Crohn’s disease having a first degree relative with UC and vice 
versa. Further evidence of a strong genetic influence in inflammatory bowel 
disease has come from twin studies with increased concordance of both UC and 
CD in monozygotic compared with dizygotic twins. The concordance rate of 
monozygotic twins with CD is higher than that of twins with UC (Tysk et a l, 
1988). These studies suggest the existence of a polygenic genetic disease in the 
aetiology of IBD rather than a simple Mendelian pattern of inheritance. The 
search for specific genetic markers has so far been unrewarding. Diseases such as 
ankylosing spondylitis and sclerosing cholangitis, which occur in association with
IBD, have strong associations with particular human leukocyte antigen (HLA) 
antigens thus suggesting indirect evidence for a genetic relation of these antigens 
with IBD. HLA class II antigens have been studied in depth with differing results 
between different population groups, e.g. there is a strong and reproducible 
association of HLA-DR2 in Japanese patients with UC, but no association is 
observed in patients with UC from the UK or the USA. Instead in this group 
association with HLA-DRB1*0103 and DRB1*1502 has been noted (Asakura et 
a l , 1982; Satsangi et a l, 1996; Duerr and Neigut, 1995). Association with 
specific genetic markers such as for anti-neutrophil-cytoplasmic-autoantibodies 
(ANCA) or for specific cytokine abnormalities e.g. TNFa and IL-lra 
polymorphisms have been sought although the relationship is generally very weak 
(Duerr and Neigut, 1995; Mansfield et a l, 1994; Yang et a l, 1995). A strong 
association between a particular locus on chromosome 16, the so called IBD1 
locus and Crohn’s disease and a locus on Chromosome 12, the IBD2 locus and 
UC have been shown in different studies (Mirza et a l, 1998; Hamlin et a l, 1999). 
Recently, it has been shown that a particular TNF-a allelic combination is a very 
strong genetic risk factor for CD and with HLA class II alleles, defines a group of 
markers on chromosome 6 that extends from HLA class II to upstream of the 
TNF-alpha gene (Plevy et a l, 1996; Hampe et a l, 1999).
1.2.2. Mucus.
Mucus represents a major component of intestinal defence and defects of this 
layer could allow the development of IBD. The mucus produced by the colon in 
patients with UC and CD is qualitatively different from that produced by normal 
subjects, reflecting a change in the structure of colonic mucin (Saitoh et a l,
61996). Mucin is a heavily sulphated glycoprotein and it has been shown that 
enzymatic desulphation by faecal bacterial sulphatases greatly increases the 
susceptibility of the mucin to degradation. The increased faecal mucin sulphatase 
activity in UC could be the result of greater quantities of mucin leading to 
bacterial enzyme induction, but this would probably result in more rapid 
degradation of secreted mucin and represents a potential target for treatment (Tsai 
et a l , 1995). Compared with healthy subjects, the different biochemical features 
of the mucin obtained from whole gut lavage fluid from IBD patients appeared to 
reflect mucosal pathological changes associated with the disease (Saitoh et a l , 
1996). It is unclear whether this is secondary to any inflammation present, or 
whether this is a primary deficit which may predispose patients to acquiring UC 
and CD. The oligosaccharide side chains of mucus glycoproteins are shorter in 
patients with UC than controls, and bind differently with monoclonal antibodies 
and lectins (Rhodes et a l , 1988; Podolsky and Fournier, 1988). The predominant 
mucin in the human colon responsible for the protective mucus layer is MUC2. 
Precursor and total MUC2 levels were significantly decreased in UC patients with 
active inflammation compared to controls, and returned to control values during 
remission of the inflammation (Van Klinken et a l , 1999). The marked increase in 
mucin synthesis that results when butyrate is added to the media in colonic biopsy 
cultures, suggests that butyrate may be an important mechanism affecting the rate 
of mucin synthesis in vivo and may also explain the therapeutic effect of butyrate 
in colitis (Finnie et a l , 1995). A similar rise in mucin synthesis with treatment 
with corticosteroids may explain in part, the therapeutic effect of steroids in UC 
(Finnie etal., 1996)
71.2.3 Mucosal Permeability.
It has been found that when the colon becomes inflamed, it becomes more 
permeable and thus absorbs usually impermeable substances such as lactulose and 
Cr-EDTA. Significant increases in blood concentrations of these molecules in 
patients with IBD have been found compared with controls, suggesting an 
increase in intestinal permeability in patients with IBD. This disturbance of the 
intestinal barrier may be due to changes in the mucosa such as erosion, ulceration, 
and oedema (Hollander, 1992; Bjamason et a l, 1995). Determining whether 
healthy first-degree relatives of patients with CD have increased permeability is of 
considerable importance because it could represent a primary predisposing factor 
which can lead to inflammation and clinical disease later in life. It has been 
discovered that increased permeability can antedate clinical manifestations of CD 
(Wyatt et a l, 1993). It has been suggested that this increase in permeability may 
be genetic in origin. Lindberg et al using monozygotic twin pairs both concordant 
and discordant for CD, found no differences in the absorption of polyethylene 
glycols between the study groups (Lindberg et a l , 1995). Although permeability 
is normal in most relatives, it has been found that a subgroup of patients had 
markedly abnormal permeability suggesting that they may represent those most at 
risk of developing CD (May et al., 1993). Another study from the same group, 
found that when relatives are challenged with acetylsalicylic acid, permeability 
increases in some of them (Hildsen et a l , 1996). The possible consequences of 
abnormal permeability have been shown by the fact that relatives have an increase 
in the number of circulating CD45RO+ B cells (Yacyshyn and Meddings, 1995). 
This suggests that a leaky intestinal barrier allows increased antigen absorption, 
which in turn, leads to an exaggerated immune stimulation reflected at a systemic
8level by increased numbers of B cells. These results give some support to the 
hypothesis of a genetically determined intestinal “leakiness” in CD and how this 
may link in to the well-documented immune abnormalities. Whether increased gut 
permeability in CD is a primary abnormality predisposing to increased mucosal 
access of luminal pathogenic factors, or is simply a consequence of mucosal 
damage induced by other mechanisms is not yet resolved.
1.2.4 Colonocvte Energy Metabolism.
It has become evident that in the normal colonic epithelium the major source of 
energy are short chain fatty acids (SCFA). The principal SCFAs are acetate, 
propionate, and butyrate, which are normally formed by bacterial fermentation of 
unabsorbed carbohydrates (Cummings and Macfarlane, 1991). These are present 
in colonic contents in relatively constant concentrations and proportions between 
different people. They are absorbed from the colonic lumen, and once inside the 
colonocytes the SCFAs undergo oxidation. In UC, colonocytes have been shown 
to utilise butyrate as an energy source less efficiently and it is postulated that low 
luminal SCFA levels in severe UC may play a part in the disease process 
(Roediger, 1980). Thus correction of these low levels may help in the treatment 
and so clinical trials of SCFA enemas have been performed. These have been 
shown to have a therapeutic benefit in patients with distal UC (Breuer et a l , 1991) 
Another trial using Plantago ovata seeds, which when they undergo colonic 
fermentation yield butyrate, showed they were as effective as mesalazine in 
maintaining remission in ulcerative colitis (Femandez-Banares et a l , 1999). This 
suggests that UC could be an expression of an energy deficiency disease of the 
colonic mucosa. Whether abnormal colonic epithelial SCFA utilisation in UC is a
9primary or secondary phenomenon, perhaps due to altered bacterial flora, is 
currently unclear.
1.2.5.Diet.
Because the main role of the gastrointestinal tract is to process and absorb food, it 
is reasonable to propose that dietary factors, possibly acting as antigens, play a 
role in the initiation or persistence of intestinal inflammation. There is less 
evidence to support this hypothesis in UC than in CD, although even in CD the 
role of dietary antigens in the aetiology of is controversial. In patients with CD, 
elemental diets i.e. where complex food substances have been chemically broken 
down into their constituent parts, appear to have a therapeutic effect, although the 
mechanism by which this occurs is uncertain. Controlled studies have suggested 
that elemental diets may be as effective as corticosteroids in inducing a remission 
in patients with acute CD (OMorain et a l , 1984). Favourable reports of diets, 
both exclusion diets (Riordan et a l , 1993), or specific diets containing substances 
such as fish oils, indigestible oligosaccharides, gum arabic and antioxidants 
(Campbell et a l , 1997) have been described by some groups but not by others. 
Population-based case-control studies of IBD especially examining dietary habits 
has shown patients with CD were more likely to have a diet featuring a high 
sucrose intake and with less intake of fibre (Kasper and Sommer, 1979; Persson et 
a l , 1992). UC patients have been shown to consume more protein than controls 
(Tragnone et al., 1995).
Dietary therapies have included an enteric-coated preparation of fish oil that has 
been shown to be effective in patients with CD (Kim, 1996). In UC, avoidance of 
dairy products has shown an improvement in a minority of patients, but
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intravenous feeding, which because it is removing all antigenic stimuli from the 
GI tract would be expected to prove beneficial, was not found to be effective and 
in some cases even made the disease worse (Burke et a l , 1997).
1.2.6. Infection.
Crohn’s disease has some parallels with other known infectious diseases e.g. 
Yersinnia, so work has been done on examining the possible role of an infectious 
agent in the aetiology of IBD. Pathological resemblances between Johne’s disease 
in cattle, which is caused by Mycobacterium paratuberculosis, and CD have 
resulted in study of the possible aetiological role of this organism (Chiodini et a l, 
1984; Sanderson et a l , 1992). Immunohistochemical studies have generally failed 
to show the organism, however studies using the polymerase chain reaction (PCR) 
have detected DNA from M. paratuberculosis in CD affected bowel much more 
often than in UC or in control bowel. However data from other studies such as 
using anti-tuberculous therapy does not support a role for M. paratuberculosis in 
Crohn's disease (Kobayashi et al., 1988; Kobayashi et a l, 1989). Multiple studies 
from one group has suggested that measles or another paromyxovirus is important 
in the aetiology of Crohn’s disease because of the possible identification of the 
virus in the vascular endothelium of the intestine in CD (Wakefield et a l, 1993; 
Wakefield et a l, 1995; Wakefield et a l, 1997). There is some epidemiological 
data supporting the idea that early infection with the measles virus either in 
childhood or prenatal exposure is a risk factor for the later development of CD 
(Ekbom et a l, 1994). This data is consistent with the possibility that CD may be a 
chronic granulomatous vasculitis reaction to a persistent infection within the 
vascular endothelium (Wakefield et a l, 1989; Wakefield et a l, 1997).
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It would appear that the balance between the protection given by mucosal forces 
and luminal microbial contents can be disturbed by changes in the environment or 
genetically determined abnormalities in the immune system could lead to a 
chronic, relapsing intestinal inflammation (Sartor, 1997). It would seem unlikely 
that the change in the environment could be due to an infection with a single 
agent. Another explanation is that more than one infectious agent can trigger IBD, 
possibly by stimulation of a susceptible potentially over-responsive immune 
system (Macpherson et al., 1996).
1.2.7.Cigarette smoking.
As UC occurs, primarily in non-smokers and ex-smokers it appears that smoking is 
somehow protective against the onset of disease (Harries et a l , 1982). This is in 
contrast to the disease course of patients with CD, which is less favourable in 
smokers than in non-smokers (Somerville et al., 1984; Timmer et al., 1998). 
Nicotine whether in chewing gum, transdermal patches or topically applied have 
all been shown to improve clinical symptoms and endoscopic appearance in 
patients with active UC (Pullan et al., 1994; Dash et al., 1999; Sandbom, 1999; 
Green et a l , 1997). To date no maintenance benefit has been demonstrated. 
Suggested mechanisms for protective effects of nicotine in ulcerative colitis are 
many and varied including direct effects on mucosal defences and physical 
properties of the mucosa e.g. increased mucus production (Zijlstra et al., 1994; 
Cope and Heatley, 1992), increased release of endogenous glucocorticoids by 
epithelial cells, (Cope and Heatley, 1992), alteration of rectal mucosal blood flow, 
decreased intestinal permeability, and effects on the immune response e.g. 
decreased mucosal eicosanoid levels (Zijlstra et a l , 1994), release of endogenous
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glucocorticoids, significant inhibition of Interleukin-2 (IL-2) and TNF-alpha 
production (Madretsma et al., 1996a; Madretsma et al., 1996b; van Dijk et al., 
1998) and an inhibition of IL-10 production (Madretsma et al., 1996b). This 
possibly explains the detrimental effects of smoking and nicotine in CD, although 
does not explain why UC and CD behave so differently with relation to smoking.
1.2.8.Drugs
As the incidence of colitis seems to have risen dramatically in the 20th century, 
one possible explanation for this is the increased use of various drugs and 
medications. One of the most likely candidates is the group known as non­
steroidal anti-inflammatory drugs (NSAIDs). These have been associated with 
initiation and relapse of IBD, possibly due to changes in eicosanoid metabolism 
and gut permeability (Rampton, 1987).
There is conflicting evidence of an increased risk of CD in users of the oral 
contraceptive pill (Boyko et a l , 1994; Lesko et al., 1985; Cosnes et al., 1999; 
Timmer et al., 1998; Lashner et al., 1989), with the prothrombotic effects of the 
drug perhaps explaining any increase in the likelihood of a worsening of Crohn’s 
Disease. A theoretical disease model has been described with intestinal ischaemia 
caused by thromboembolic events in small blood vessels supplying the mucosa, 
which trigger a chain of events that culminate in clinical IBD (Koutroubakis et al., 
1996), although most of these studies it is hard to isolate the effect of the oral 
contraceptive pill whilst not including the effect of smoking.
There are some individual reports relating antibiotic usage to relapse of IBD and a 
possible explanation for this is due to changes in colonic bacterial flora although
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some authors paradoxically advocate the use of antibiotics in severe colitis 
(Peppercorn, 1993).
1.3.The Role Of Colonic Epithelium In The Immunology Of The Bowel
1.3.1 .Epithelial Cell
The colonic mucosa is the layer of the large bowel which divides the luminal 
contents of the colon from the large bowel structure. It forms the absorptive 
surface and covers the lamina propria, which is found immediately beneath the 
epithelium and the crypts. The main cell populations in the colonic epithelium are 
the colonic epithelial cells and mucus secreting goblet cells. Intraepithelial 
lymphocytes infiltrate throughout the epithelium. The primary function of the 
intestinal epithelium is the absorption of nutrients, water and electrolytes from the 
gut lumen into the body. The colonic epithelial cell was originally thought of as a 
barrier, with a role in transport of nutrients, but probably immunologically inert. 
However, during the last two decades it has been realised that the epithelium itself 
is instrumental in the inflammatory process.
The evidence that the epithelial cell could be involved in the immunological 
response of the mucosa first appeared in 1970 with the discovery of IgA 
antibodies. This demonstrated that the function of IgA is dependant on epithelial 
cells. It was shown that mucosal IgA is synthesized by plasma cells as a dimer. 
This dimer then combines with a transmembrane polypeptide produced by 
epithelial cells, called secretory component, to form secretory IgA (Tomasi, Jr., 
1970). This peptide protects the IgA dimer from luminal proteolysis (Mostov et 
al., 1984). It was also reported that IgM function at mucosal surfaces was in the
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form of secretory IgM, where IgM binds to secretory component (Brandtzaeg, 
1973).
The primary function of the intestinal epithelial cells is to act as a barrier between the 
environment and the host. As the epithelial cells are also the first cells to come in 
contact with many pathogens, it is likely that they play a critical role in alerting the 
immune system located in the underlying intestinal mucosa. These in turn are 
involved in the recruitment of circulating immune cells during the inflammatory 
response.
Within the last decade colonic epithelial cells have been increasingly recognised as 
having an active role in inflammation, with roles such as presenting antigens via 
class II MHC expression and thus acting as antigen presenting cells to T cells 
(Mayer et al., 1991; Lowes et a l , 1992). Although epithelial cells in the normal 
small intestine express MHC Class II determinants, only epithelial cells in the 
inflamed colon do so (Selby et a l, 1983) Colonic epithelial cells also express 
adhesion molecules e.g. intracellular adhesion molecule-1 (ICAM-1) (Kvale and 
Brandtzaeg, 1995) and can produce soluble inflammatory mediators e.g. arachidonic 
acid derivatives (Dias et a l , 1992), platelet activating factor (Ferraris et a l , 1993), 
cytokines (Hedges et a l , 1992; Eckmarm et al, 1993; Jung et al, 1995; Schuerer- 
Maly et al, 1994; Gross et al, 1995), and chemokines (Mazzucchelli et al, 1994; 
Eckmann et a l, 1994), all of which allow communication between cells of the 
immune system Colonic epithelial cells appear to provide a set of signals to allow 
and promote the activation of the inflammatory response in the early phases of 
attack from bacteria etc.
Despite the obvious proximity of various populations of white cells, e.g. 
macrophages, lymphocytes to the epithelial cells in the mucosa, little if any work
has been done on the relationship between these two cell populations. Almost all 
work concentrates on isolated groups of cells e.g. epithelial cells on their own. It 
is very likely however, that when the local macrophage and lymphocyte 
populations are stimulated by antigens, they in turn then influence the epithelial 
cells. This in turn will lead to mediators being released from the white cells and 
acting locally on the epithelial cells. No information about which mediators are 
important or even what happens when the two populations of cells are in contact 
is available.
1.3.2 Intra-Epithelial Lymphocytes
The exact role of intra-epithelial lymphocytes (IEL) in the gastrointestinal mucosa 
is poorly understood (Croitoru and Ernst, 1992; Cerf-Bensussan and Guy-Grand,
1991). It is thought that IEL play a central role in local intestinal immunity and 
are likely to be important in defence against gastrointestinal neoplasms. There are 
two populations of IELs; the predominant group is the CD8+ (suppressor- 
cytolytic) subset of T lymphocytes that display the a/p T-cell receptor (TCR) and 
show evidence of activation. The second group of T cells are mostly CD4' and 
bears the y/8  form of TCR. The majority of the lamina propria T lymphocytes 
belong to the a/p form of T cells with the minority being y/5 cells (Trejdosiewicz,
1992).
Animal models of inflammatory bowel disease have shown that a chronic 
inflammatory bowel disease occur spontaneously in mouse models where targeted 
deletions of immune response genes have taken place. These so called knockout” 
mice models are able to develop colitis with a wide range of products deleted e.g. 
IL-2(Sadlack et al., 1993), IL-10 (Kuhn et a l , 1993), T cell receptor (Mombaerts
et al., 1993), TGF-0 (Kulkarni et al, 19)3). Recently important studies using 
similar animal models have demonstrated that when T lymphocytes are 
transferred into T-cell deficient mice thei cofitis will occur (Rudolphi et al,
1994). It would appear from experiments ising these models that most events h 
the inflammatory response both pro-inflanmatcry and regulatory are controlled 
by CD4+ T lymphocytes (Elson et al., 199§Elson et al, 1995). If these knockout 
nice are kept in sterile environments then colitis does not occur. This would 
suggest that the mucosal inflammation is tntigen dependant and the responsible 
antigens originate from intestinal bacteria (Schultz et al., 1999; Sellon et al, 
1998). These studies show the key role of different parts of the immune response 
and do suggest an important role of T celk especially intraepithelial lymphocytes 
in the pathogenesis of the immune response.
1.4.1mmunological Factors In IBD
It is known that IBD involves a widespreal activation of the immune system and 
many of the effects of inflammatory bowd disease are caused by the excessive 
and tissue damaging chronic inflammatory response in the gut wall Down- 
regulating this response allows the micosa to heal and function of the 
gastrointestinal tract to return to normal. Corticosteroids are extremely good at 
inhibiting immune responses aid in the mijority of patients are the mainstays of 
treatment. However they merely control thj inflammation and do not permanently 
alter the natural history of IBD.
The inflammatory reaction involves ealy expression of surface achesion 
molecules on vascular endothelial cels, with consequent migration and 
subsequent activation of circulating leukocytes into the colonic mucosa
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(Schuermann et a l, 1993; Koizumi et a l, 1992). This activation is attributed to 
the synthesis of inflammatory mediators and cytokines that in turn contribute to 
the pathological features of IBD. These mediators are produced not only by both 
resident and newly recruited mucosal inflammatory cells such as neutrophils, 
macrophages and mast cells, but also by colonic epithelial cells (MacDonald and 
Murch, 1994).
1.5. Cytokines and Inflammatory Bowel Disease
Cytokines are glycosylated peptides ranging in size from 6  to 30 kilodaltons 
secreted by a wide variety of cells in response to immunological challenge, such 
as infection, inflammation or tissue injury. Very small quantities are known to 
have powerful biological effects. Even in picomolar concentrations cytokines 
elicit numerous responses from target cells. They are therefore important in all 
aspects of the regulation of the immune response. They are involved in both the 
initiation and the amplification of the immune response (MacDermott and 
Stenson, 1988). Cytokines can be sub-divided into the following different 
families; Interleukins (e.g. Interleukin-1), Interferons (e.g. Interferon-a, 
Interferon-y), Tumour necrosis factor family (e.g. TNF-a), Colony Stimulating 
factors (e.g. G-CSF, EPO), Chemokines (e.g. IL-8  GRO-a, ENA-78, MIP-la, 
MCP-1, RANTES, Eotaxin) and Growth Factors (e.g. TGF-pi, TGF-a). Some 
cytokines are thought to have mainly pro-inflammatory effects for example, 
Interleukin 1 (IL-1), Interleukin 8 (IL-8), and some are found to have mainly anti­
inflammatory actions e.g. Interleukin 10 (IL-10).
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1.5.1 Interleukin -1
IL-1 was one of the first cytokines to be identified in experimental animals and 
humans. It was found that a soluble factor was able to cause fever and was thus 
initially described as “endogenous pyrogen” (Atkins, 1960). It was soon found 
that in addition to causing fever, it could mediate many other fimctions. These 
include prominent pro-inflammatory effects, for example, induction of acute 
phase proteins, neutrophilia and an increase in synthesis of serum amyloid A 
protein (Dinarello, 1984). It has also been known by a wide variety of names 
including leukocyte endogenous mediator, lymphocyte-activating factor, 
mononuclear cell factor, catabolin, osteoclast-activating factor and haemopoietin 
(Dinarello, 1989).
Although IL-1 can be produced by a wide variety of both immune and non- 
immune cell types, most IL-1 is produced by monocytes and macrophages. Two 
isoforms of the protein have been identified although both use the same cell 
surface receptor. IL-1 a  is mainly membrane associated and IL-lp is mainly 
secreted. Both isoforms are able to modulate the fimctions listed above and also 
have other major effects. These include acting upon endothelial cells leading to 
the accumulation of both platelets and leukocytes, stimulation of collagenase 
production, stimulation of fibrogenesis, increased production of prostaglandins 
and leukotrienes, and activation of mature T and B cells (Dinarello, 1989). Raised 
levels of IL-1 are found in a wide variety of pathological conditions including 
septic shock, rheumatoid arthritis, acute and chronic myeloid leukaemia and 
inflammatory bowel diseases.
Organ cultures of inflamed mucosa from patients with IBD were found to produce 
increased amounts of IL-1 p (Reimund et al., 1996). Increased concentrations of
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IL-1 have been reported in active ulcerative colitis although the exact site of 
synthesis remains unclear (Ligumsky et al., 1990). IL-1 production in stimulated 
peripheral blood mononuclear cells from patients with active ulcerative colitis and 
Crohn’s disease was significantly increased compared to controls. The levels 
correlated with serum C-reactive protein. Furthermore when patients were in 
clinical remission IL-1 levels fell to normal (Nakamura et al, 1992; Mazlam and 
Hodgson, 1992). When looking at mononuclear cells from the intestinal lamina 
propria from patients with active ulcerative colitis and Crohn’s disease again 
increased levels of IL-lp were found. These findings were confirmed when 
looking at the supernatant of colonic mucosal biopsies from patients with active 
inflammatory bowel disease (Mahida et al., 1989).
It has been shown that pre-treatment of rabbits with a small dose of IL-1 reduces 
subsequent inflammation in an immune complex model of inflammatory bowel 
disease. This is very similar to the effect seen in shock induced by endotoxin. The 
precise mechanism of this is unknown but it may be that a small dose of IL-1 
induces gene transcription of a protective factor or factors that result in the down 
regulation of inflammation (Cominelli, 1990).
1.5.2 Interleukin-1 Receptor Antagonist
In 1990 a new peptide was purified, cloned and expressed which is a natural 
antagonist of IL-1 and has been named Interleukin-1 receptor antagonist 
(IL-lra)(Eisenberg et al., 1990). This specifically blocks IL-1 activity and not 
other pro-inflammatory mediators. Two structural variants have been described; a 
secreted form primarily produced by mononuclear cells (Eisenberg et al., 1990) 
and an intracellular form found in epithelial cells (Haskill et al., 1991). Elevated
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plasma and tissue levels have been detected in various inflammatory diseases and 
it has been suggested that it may be part of the homeostatic mechanism designed 
to down regulate the immune response (Dinarello and Wolff, 1993). It has been 
detected in normal and inflammatory bowel disease affected tissue (Isaacs et al., 
1992). The likely sources of IL-lra are lamina propria mononuclear cells and 
epithelial cells (Bocker et al 1998). It has been suggested that an imbalance in the 
relative proportions of IL-1 and IL-lra could result in an inability to produce an 
appropriate inflammatory reaction.
1.5.3.Tumour Necrosis Factor-a
Two major forms of tumour necrosis factor exist, tumour necrosis factor-a (TNF- 
a  or cachectin) and tumour necrosis factor-p (TNF-p or lymphotoxin). They are 
both key inflammatory cytokines that share several properties with IL-1. TNF-a 
was initially described in the peripheral circulation of animals with severe 
bacterial infection. It was found to be able to induce tumour destruction (Carswell, 
1975). This cytokine is derived primarily from macrophages and monocytes, 
although lymphocytes, eosinophils and natural killer cells can produce TNF-a 
(Tan et a l , 1993). It is one of the prime mediators of an inflammatory response 
producing a wide range of biological responses (Beutler and Cerami, 1989; 
Tracey, 1986). It induces fever, hypotension, leucopaenia and tissue injury. 
TNF-a is also responsible for the induction of neutrophils, eosinophils, 
monocytes/macrophages and lymphocytes and changes in vascular endothelium 
leading to the accumulation of white blood cells. The clinical observation that 
patients with severe infections and generalised wasting have high circulating
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levels of TNF-a, suggest that this cytokine may be important in patients with 
chronic illness.
The exact role of TNF-a as a mediator in Crohn’s disease or ulcerative colitis 
remains unclear. Circulating levels of TNF-a have been measured in several 
studies with conflicting results. Raised levels have been shown in both paediatric 
and adult populations with Crohn’s disease particularly in those with active 
disease (Murch et al 1991; Maeda et al, 1992). However, other studies have 
shown normal levels in both of these populations (Hymas, 1991). The levels of 
soluble TNF-a receptors that have neutralising activity may explain the apparent 
disparity between these results. There is some evidence that there are higher levels 
of these receptors in the serum of patients with Crohn’s disease compared to 
controls. The concentration of TNF-a also has been reported to be higher in the 
stools of patients with active IBD, with a return to normal values when the disease 
is in remission (Braegger, 1992). Evidence that the mucosa in IBD is the source of 
the TNF-a was initially found with higher numbers of cells secreting TNF-a in 
mucosal biopsies obtained from patients with IBD than those from normal 
intestine. Other studies however, have not shown consistently raised levels of 
TNF-a using a variety of methods such as in situ hybridisation (Cappello et al.,
1992) or PCR looking for gene transcripts (Isaacs et al., 1992). It is likely that 
variable patient selection, tissue collection methods and diverse experimental 
methodology can explain some of these differences, but it would suggest that 
TNF-a is not consistently raised in IBD. Elevated levels also appear in other 
inflammatory conditions of the gastrointestinal tract, suggesting that this cytokine
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may be a secondary phenomenon rather than have a primary role in the 
pathogenesis of IBD.
Powerful evidence that TNF-a has an important role in IBD comes with the use of 
monoclonal antibodies directed against TNF-a in the treatment of patients with 
Crohn's disease. This was initially described in two patients with severe disease in 
1993 (Derkx et a l , 1993). Usually this treatment has been used in patients with 
the most severe disease i.e. steroid dependent Crohn's disease. It would appear 
from initial results that it is more beneficial in Crohn's disease than in ulcerative 
colitis (Baert et al., 1999; Targan et al., 1997). This is especially true for those 
patients with fistulating Crohn’s disease (Targan et al., 1997; Rutgeerts et al., 
1999; Ricart and Sandbom, 1999; Lofberg, 1999; Mouser and Hyams, 1999; 
DHaens et al., 1999). Such is the efficacy in patients with Crohn’s disease that it 
has now become licensed for treatment in both the USA and the UK (Kombluth, 
1998). Since this initial report nearly 12000 patients have been treated with the 
monoclonal antibody with generally favourable results.
1.5.4. Interferon-y
The name interferon was initially used to denote a substance capable of conferring 
the ability to resist against viral infection to various cells. However, the term now 
encompasses a large family of cytokines with both anti-viral and immune 
modulatory properties. This family is composed of three main types of interferon, 
which have been designated IFN-a, IFN-(3, and IFN-y. Each of these possesses 
variable degrees of anti-viral and immune modulatory activity. Interferon-y is 
produced mainly by natural killer (NK) and T cells (Kawase et al., 1983; Handa et
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al., 1983). It is a weak anti-viral but a potent immune modulator. It also induces 
expression of the major histocompatibility complex (MHC) (Ruemmele et a l, 
1998; Giacomini et a l, 1988), macrophage activation (Schultz et a l, 1977; Heise 
and Virgin, 1995), modulation of B-cell responses and enhancement of T-cell 
mediated cytotoxicity (Yamada et a l, 1990; Yeoman and Robins, 1988). The 
most characteristic of these functions is the induction of MHC class II molecule 
expression on antigen-presenting cells (Fruh and Yang, 1999; Suda et a l, 1995). 
This may be particularly important when considering the intestinal mucosa, as 
both classical and non-classical antigen-presenting cells are distributed throughout 
the mucosa.
The possible role of IFN in inflammatory bowel disease has been examined in 
many studies. The level in the serum of patients has been measured and also the 
production by peripheral blood mononuclear cells usually with inconsistent 
results. For example, lowered serum levels of IFN-y have been detected in patients 
with Crohn’s disease and ulcerative colitis (Capobianchi et a l, 1992). However, 
other studies have failed to demonstrate this. When looking at sub-populations of 
cells in inflamed mucosa, no spontaneous increase in IFN-y production was seen 
in the supernatant of unstimulated lamina propria mononuclear cells (Lieberman 
et a l, 1988; Camoglio et a l, 1998). In fact, after stimulation with IL-2 or 
phytohaemagglutinin activation, these cells produced less IFN-y than cells from 
non-inflamed mucosa (Lieberman et a l, 1988).
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1.5.5. Interleukin-6
Elevated levels of Interleukin-6  (IL-6) in both serum and colonic mucosa have been 
demonstrated in IBD (Mahida et a l , 1991a). This is confirmed by the detection of 
EL-6  mRNA transcripts in actively inflamed tissues from IBD patients (Woywodt et 
a l , 1994). IL-6  positive IBD specimens were also found positive for IL-113 and it has 
been suggested that the expression of IL-6  may provide an additional mediator in 
IBD (Stevens et a l , 1992). Also in common with IL-1 p and other mediators IL-6 
could lead to the inflammatory response characteristic of IBD, or IL-6 could play a 
protective role by inducing hepatic acute phase proteins. Organ cultures of involved 
IBD mucosa spontaneously produced increased amounts of IL-6  compared to 
normal mucosa (Hosokawa et a l , 1999). A significant relationship between serum 
IL-6  antigen and platelet count has been reported in IBD. It has been suggested that 
IL-6  may stimulate megakaryocyte activity and result in thrombocytosis in disease 
characterised by chronic inflammation (Heits et a l , 1999). Taken together these 
reports suggest that elevated serum IL-6  levels may be associated with the elevated 
platelet counts frequently seen as part of the acute phase response in IBD patients.
1.5.6.Interleukin-4
Interleukin-4 (TL-4) was originally identified in 1986 by the functional screening 
of a mouse T-helper cell cDNA library (Lee et a l , 1986; Noma et a l , 1986). The 
human equivalent was then isolated from a concanavalin-A stimulated human 
T-cell cDNA library based on homology with the murine sequence (Yokota et a l , 
1986). It was initially named B-cell stimulatory factor-1 or B-cell growth 
factor-Ion the discovery of its capacity to promote the entry of resting B-cells into 
the S-phase of the cell cycle (Rabin et a l , 1986; Paul and Ohara, 1987). The
human gene is located on chromosome 5 within 50 kilobase pairs of the gene for 
IL-13 (Arai et al., 1989). It is secreted as a 154 amino acid precursor that is 
subsequently cleaved to produce a 129 amino acid secreted peptide with a 
molecular weight of a 15 kDa. IL-4 is primarily produced by T-cells although 
mast cells also produce it (Brown et a l, 1987). It has since been discovered that 
IL-4 has a wide range of activities such as the augmentation of MHC class II 
antigen expression on B-cells (Stuart et al., 1988), stimulation of mast cells and 
T-cells (Mosmann et al., 1986), modulation of NK cells (Conlon et al., 1989) and 
stimulation of haemopoietic cells (Peschel et a l, 1987). It is known that IL-4 
inhibits the release of pro-inflammatory cytokines IL-lp, TNF-a and IL-6  from 
monocytes (Te Velde et al., 1990), increases the production of EL-Ira (Jenkins 
and Arend, 1993). Probably the most biologically important effect of IL-4 is its 
modulation of antibody production and its role in the allergic response (Saleem et 
al., 1998; Callard et al., 1991).
Despite the variety of effects on several different immune cells and functions 
relevant to the modulation of immunity and the possible down-regulation of the 
immune response, little is known about the role of IL-4 in IBD. IL-4 has been 
shown to modulate the proliferation and cytotoxicity of lamina propria 
mononuclear cells. This effect is differentially expressed in the different forms of 
IBD, with IL-4 inhibiting lymphokine activitated killer cells in ulcerative colitis 
and in control patients but not in Crohn’s disease patients (West et a l, 1996). 
Defective deactivation of intestinal macrophages by IL-4 has also been reported in 
IBD patients. IL-4-mediated regulation of mononuclear phagocyte effector 
functions is disturbed in EBD (Schreiber et al., 1995a).
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1.5.7.1nterleukin-10
Interleukin-10 is a 35 kD homodimeric cytokine, which was originally described as 
Th2-cell-derived cytokine (Fiorentino et a l, 1989). Recent studies have shown that 
EL-10 is produced by a variety of cells, including Th2 cells, mast cells and cells of 
the macrophage lineage. This cytokine at concentrations of 10 ng/ml or less is an 
effective inhibitor of cytokine generation by monocytes stimulated with IFN-y or 
LPS and thus it was originally known as Cytokine Synthesis Inhibitory Factor 
(CSIF). It acts as a suppressor through the deactivation or inhibition of monocytes 
and macrophages (De Vries, 1995). This would suggest the likelihood of an 
important role of IL-10 in the pathogenesis of chronic inflammatory diseases (de 
Waal Malefyt et al, 1991). This was strengthened with the discovery that mice 
deficient in EL-10 gene, so called “knockout” mice spontaneously develop an 
enterocolitis (Kuhn et a l , 1993). This supported the theory that IL-10 (or rather 
the lack of it or an effective form of it) is a key factor in the evolution of chronic 
gastrointestinal diseases. A possible explanation of the continuance of 
inflammation in IBD is the abolition of tolerance of bacterial inflammation. This 
inhibition of tolerance of bacterial flora is seen in experimentally induced colitis 
in EL-10 deficient mice, which is restored when IL-10 is infused (Duchmann et 
a l , 1996).
Using PCR, mRNA for IL-10 has been detected in human intestinal mucosa. 
Actively inflamed mucosa apparently contains very high levels of IL-10 mRNA 
(Nielsen et a l , 1996). Again whether this is a primary or a secondary 
phenomenon is as yet unclear. Patients with both UC and Crohn’s disease have 
high circulating levels of EL-10 (Kucharzik et a l, 1995). This has led to the 
suggestion that EL-10 may act as an anti-inflammatory agent in IBD and thus
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studies have been performed using IL-10 in the treatment of IBD. These studies 
have generally shown that in ulcerative colitis remission can be induced with 
IL-10 although little effect is seen with CD (Schreiber et a l, 1995b).
1.5.8. Interleukin-13
EL-13 is a 132 amino acid protein secreted predominantly by activated CD4+ T cells. 
The human gene is located on chromosome 5 (McKenzie et a l, 1993). It is known to 
be a potent suppressor of IL-la, IL-ip, IL-6 , IL-8, MEP-la and TNF-a produced by 
activated monocytes and macrophages (Minty et al, 1993), (McKenzie et al, 1993), 
(Zurawski and De Vries, 1994), (de Waal et al, 1993) and endothelial cells 
(Marfaing-Koka et al, 1995). In addition IL-13 induces the production of IL-1 
receptor antagonist (Muzio et al, 1994) and modulates the expression of cell surface 
proteins such as class II MHC antigens (de Waal et al, 1993). The results about the 
EL-13 production in EBD patients are contradictory so far (Radford-Smith and 
Jewell, 1996). The inhibitory effect of IL-13 on TNF-a and IL-6  production in 
differentiated macrophages was diminished in EBD patients and the anti­
inflammatory activity of IL-13 was found partially reduced in patients with active 
EBD (Kucharzik et a l, 1996), while IL-13 has been found to inhibit nitric oxide 
production in activated colonic epithelial cells (Kolios et a l, 1998).
Although IL-4 and 11-13 are known to share the same cellular receptor (Gauchat et 
a l, 1997) and many biological functions, there are known to be some important 
differences between the two cytokines. The most noticeable is that EL-13 does not 
exhibit the ability of IL-4 to induce T cell proliferation (de Waal et a l, 1995;Spits 
et a l, 1987). Similarly, regulation of production of the two cytokines is not 
identical. Following stimulation of peripheral blood T cells, production of IL-13
28
mRNA is rapidly induced and long lasting whereas IL-4 production is of much 
slower onset and is more transient (de Waal et al., 1995). IL-13 production by 
T-cells is inhibited by CD3 ligation and is enhanced by cyclosporin whereas the 
converse is true for IL-4 (Van der Pouw Kraan TC et al., 1996).
1.5.9. Summary
The aetiology of IBD appears to be immunologically mediated. Cytokines with their 
inflammatory and regulatory properties appear to play a role in pathogenesis of UC 
and CD. Some cytokines have protective effects that are important in the resistance 
to infectious agents and possibly in the healing phase of inflammation and an 
imbalance of the inflammatory and protective properties of the cytokine network 
may determine why the inflammation becomes chronic and the tendency of these 
diseases to flare up again.
The evidence accumulated so far would suggest that Crohn’s disease has a T 
helper type 1 response (Thl). Thl cells secrete interferon-y, lymphotoxin and 
interluekin-2, whereas Th2 cells secrete IL-4, IL-5, IL-6 , IL-9 and IL-10. There is 
a single report that IL-4 transcripts are elevated in the early ileal lesions of 
recurrent Crohn’s disease (Desreumaux et a l , 1997) but this may be a transient 
response in special circumstances, and as already stated IL-6  does seem important 
in Crohn’s disease. Initial evidence suggests that ulcerative colitis is more likely 
to be a Th2 response as there are features suggestive of an antibody mediated 
autoimmunity, although the evidence for this is weak. There is the association 
with primary sclerosing cholangitis, another antibody mediated disease, and some 
patients also have autoantibodies to the perinuclear component of neutrophils 
(p-ANCA) (Saxon et a l , 1990). The inflamed bowel is filled with IgG plasma
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cells and IgG co localising with complement C3b can be seen on the surface of 
epithelial cells (Halstensen et a l, 1993). Against the idea of this being a Th2 
response there are groups that have shown that IL-4 is actually decreased in UC 
(Karttunnen et a l, 1994; West et a l, 1996). CD4 cells from patients with UC 
produce large quantities of IFN-y as well as EL-5.
It also seems that environmental factors, for example dietary or microbial, trigger 
an inappropriate mucosal inflammatory response in individuals having either a 
genetically abnormal immune system, gut permeability, mucus and/or colonocyte 
metabolism. Although some clues about the pathogenesis of IBD are slowly 
becoming apparent, the mechanisms underlying why the mucosal inflammation 
becomes chronic and relapses of quiescent disease in patients with IBD are 
unknown. For example, is the chronicity of the inflammation due to a persistence 
of a stimulus of inflammation? Is it due to a down-regulation of the anti­
inflammatory side of the immune response? (Podolsky, 1991) If we are to 
improve our understanding of the pathogenesis of IBD, and thus its treatment then 
these questions need to be answered.
1.6. Chemokines
1.6.1. Structure and Function of Chemokines
The discovery and characterisation of interleukin-8 (IL-8) revealed the existence 
of a large sub-group of inducible, pro-inflammatory cytokines (Baggiolini et a l,
1989). Chemokines are generally small heparin-binding polypeptides, which are 
involved in attracting effector cells to the site of inflammation and are also 
responsible for activating specific leukocytes populations (Rollins, 1997; Lindley 
et a l, 1993). A wide variety of cell types e.g. immune cells, fibroblasts,
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endothelial cells and mesangial cells, are known to express and secrete these 
cytokines when stimulated e.g. by IL-1, TNF, IFN-y, LPS (Baggiolini et a l ,
1994). Chemokines are structurally related by possessing four conserved cysteine 
residues that form two disulphide bonds and establish the tertiary structure of the 
protein. They are then divided into sub-families based on the arrangement of the 
conserved cysteine residues in the molecule (Oppenheim et a l , 1991). Four 
groups of chemokines have now been defined.
The C-C sub-family in which the first two cysteine residues are adjacent, include 
monocyte chemotactic protein-1 (MCP-1) and Regulated on Activation, Normal T 
cell Expressed and Secreted (RANTES)) and preferentially act on mononuclear 
cells. MCP-1 is a potent chemoattractant for monocytes and macrophages 
(Leonard and Yoshimura, 1990) as well as for CD4+ and CD8+ T lymphocytes 
(Loetscher et a l , 1994; Taub et a l, 1995). In addition to monocytes, RANTES is 
a selective chemotactic agent for CD4+ T cells (memory T cells) (Schall et a l ,
1990) and eosinophils (Kameyoshi et a l , 1992).
The C-X-C sub-family, with EL-8 the prominent member, has an aminoacid 
residue between the first two cysteine residues and its primary function is that it 
attracts and activates neutrophils (Baggiolini et a l , 1989).
The discovery of lymphotactin (Kelner et a l , 1994) has shown the existence of a 
third group, named C subfamily, which lacks two (the first and third) of the four 
conserved cysteine residues. Lymphotactin is a chemotactic cytokine for 
lymphocytes, but not neutrophils and monocytes and it is produced abundantly by 
CD8+ T cells (Kennedy et a l , 1995).
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Finally, the recently defined CX3C chemokine e.g. fractalkine, is an integral 
membrane protein with a chemokine domain in its N-terminus thus denoting a 
new chemokine group. This subfamily differs from the other chemokines by the 
presence of three amino acids intervening between the first two cysteine residues 
(Bazan e ta l, 1997).
The C-X-C subfamily is further divided into those with or without an ELR motif, 
preceding the first cysteine residue. This motif consists of three aminoacids Glu- 
Leu-Arg near the amino terminus and this plays a crucial role in receptor-ligand 
interactions on neutrophils. Chemokines with the ELR motif (IL-8 , Gro-a, Gro-p, 
Gro-y, ENA-78 and NAP) act primarily on neutrophils as chemoattractants and 
activators. In addition, the ELR containing CXC chemokines are known to induce 
angiogenesis. C-X-C chemokines which lack the ELR domain (MIG, IP 10 and 
PF-4) have no neutrophil chemotactic activity and are angiostatic (Strieter et al., 
1995).
Accumulation of leukocytes in the extravascular space requires a series of co­
ordinated signals, including the expression and activation of cellular adhesion 
molecules as well as the generation of chemotactic gradients by the cells in the 
extravascular compartment (Huber et a l , 1991). Chemokines are key to several 
levels of this multi-step process, which requires four sequential steps: rolling, 
triggering, adhesion and migration (Adams and Shaw, 1994). Initially, leukocytes 
become attached to the endothelial layer and then roll in a slower flow along the 
vessel wall, thus enabling them to sample the environment for further stimuli. 
Selectins, which are expressed in both endothelium and leukocytes, are known to
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mediate the rolling of leukocytes. However, without a further triggering factor 
leukocytes will detach themselves from the vessel wall (Springer, 1994).
The next step that promotes strong adhesion is due to integrin adhesiveness and 
again involves chemokines (Vaddi and Newton, 1994). The stimulated leukocytes 
spread and become firmly attached to the endothelial layer through the interaction 
of integrins on the leukocytes with adhesion molecules on the endothelial cells 
(Adams and Shaw, 1994). Interleukin-8  is an important example of a neutrophil 
triggering factor (Rot, 1992), while both RANTES and MIP-lp activate the T cell 
integrins, VLA-4 (Very Late Antigen 4) and LFA-1 (Leucocyte Function 
Antigen-1) (Gilat et al., 1994). After this strong adhesion to the endothelium, 
leukocytes will then migrate into the underlying tissue along a chemotactic 
gradient. Differential migration of subsets of leukocytes into tissue depends on the 
type of integrin expressed on the leukocytes and on the interaction with a specific 
adhesion molecule on the endothelial surface. This expression in turn depends on 
the type of endothelium involved and on the stimulating chemokine. This complex 
mechanism allows migration of the correct leukocyte to a specific site.
1.6.2.The Role Of Chemokines In IBD
IL-8 is likely to be important in IBD as this cytokine induces neutrophil chemotaxis 
and thus may explain the accumulation of large number of neutrophils in the 
intestinal inflamed mucosa in IBD (Cole et a l , 1996). High levels of IL-8 are found 
in inflamed colonic mucosa, from patients with UC and CD compared to controls 
and IL-8 mRNA has been found in colonic biopsies from IBD patients, using PCR 
amplification and in situ hybridisation (Daig et al, 1996; Isaacs et al, 1992). In situ 
hybridisation revealed strong IL-8  signals in the affected mucosa in active IBD,
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but not in the mucosa of uninvolved bowel segments or in normal mucosa from 
controls. Results from patients with acute appendicitis found IL-8-expressing cells 
in the mucosa suggesting that IL-8 is not specific in the pathogenesis of IBD, but 
it is involved in many different types of intestinal inflammation (Mazzucchelli et 
a l, 1994). Because human colonic epithelial cells have been shown to express 
IL-8 , it has been suggested that these colonic epithelial cells may contribute to 
neutrophil extravasation and tissue infiltration in intestinal inflammation (Biynskov 
eta l, 1992).
Colonic epithelial cell lines have been shown to be a significant source of IL-8 after 
stimulation by pro-inflammatory cytokines e.g. IL-1 a  and TNF-a or 
lipopolysaccharide (Eckmann et al., 1994; Schuerer-Maly et al, 1994; Gross et al,
1995).
RANTES, another monocyte attracting C-C chemokine, was found to be increased 
in the intraepithelial lymphocytes in the lamina propria of patients with IBD 
compared with controls (Mazzucchelli et a l, 1996). Using in situ hybridisation, it 
was demonstrated that the monocyte attracting chemokines, RANTES, MIP-la 
and MIP-lp were expressed by macrophages, T lymphocytes, and endothelial 
cells in actively inflamed tissue but rarely expressed in non-inflamed sections 
from IBD. The frequency of chemokine-expressing cells was significantly greater 
in severely inflamed than in moderately or mildly inflamed tissue. For example, 
RANTES was expressed by T lymphocytes in lamina propria from normal colon, 
although in very small amounts (Grimm and Doe, 1996). The increased number of 
MCP-1 and RANTES mRNA-expressing cells in mucosa from patients with IBD 
suggests that these cytokines play a role in the recruitment of peripheral blood 
monocytes and the expression of the MCP-1 gene in vessel-associated cells may
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indicate its involvement in mechanisms regulating the adhesion of blood 
monocytes to endothelial cells (Mazzucchelli et a l , 1996).
This suggests that colonic epithelial cells are important in chemokine production 
and may be especially important in the early recruitment of circulating immune 
cells in intestinal inflammation.
1,7. Other Inflammatory Mediators
The term eicosanoid is used to describe breakdown products from the membrane 
phospholipids into arachadonic acid. These subsequently form bioactive 
substances with both pro-inflammatory and anti-inflammatory activity, which 
include prostaglandins, thromboxanes and leukotrienes. These appear to be 
important in the pathophysiology of IBD (Yang, 1996) as concentrations of all the 
eicosanoids have been found to be significantly increased in gut lavage fluid from 
patients with IBD (Hommes et a l , 1996). Efforts to manipulate this have been 
made by inhibiting the production of potentially damaging eicosanoids in patients 
with IBD. Diets with fish oil are known to change intestinal eicosanoid synthesis, 
however, its effectiveness in patients with active or inactive inflammatory disease 
is controversial (Casellas and Guamer, 1996).
1.7.1 .Prostaglandins.
Prostaglandins (PG) were the first eicosanoids to be studied in IBD, their 
increased production in active disease demonstrated by in vitro culture of 
colorectal biopsies and in vivo rectal dialyses (Rampton and Hawkey, 1984; 
Lauritsen et a l, 1989; Baumeister et a l, 1996). A link between eicosanoids and 
IBD was initially discovered when it was discovered that the mucosa of patients
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with IBD contained high levels of prostaglandins whose synthesis decreased with 
the use of sulphasalazine (Sharon et al., 1978). Luminal release of PGE2 has been 
found to be significantly higher in patients with UC than in patients with CD, 
Clostridium difficile infection or control subjects (Lauritsen et a l , 1988). 
Furthermore, there was a significant increase in luminal PGE2 in first-degree 
relatives and this suggested that increased synthesis of prostaglandins might 
constitute an abnormal response because of a genetic predisposition (Ahrenstedt et 
al., 1994). The increased PGE2 production found in the inflamed mucosa in active 
UC may be caused by activated macrophages and eosinophils (Raab et al., 1995). 
Because increased prostaglandin synthesis can cause changes in both intestinal 
motility and by inducing mucosal secretion of water and electrolytes it could 
account for the diarrhoea seen in IBD (Bern et al., 1989). It would also have a 
protective effect on the mucosa by increasing mucus secretion, altering mucosal 
blood flow and suppressing immune and inflammatory cell function (Rampton 
and Hawkey, 1984; Lauritsen et a l, 1989; Rampton and Collins, 1993). The 
importance of eicosanoids in IBD could be the explanation why NSAIDs can 
cause the adverse effects in IBD by inhibition of prostaglandin synthesis (Davies,
1995).
1.7.2.Leukotrienes
Another group of the eicosanoids, the leukotrienes, are involved in the 
inflammatory cascade in IBD. Leukotrienes are likely to contribute to mucosal 
inflammation particularly by recruitment and activation of neutrophils. Both in 
vitro and in vivo studies have suggested that increased mucosal production of 
leukotrienes occurs in patients with active IBD (Rampton and Hawkey, 1984;
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Lauritsen et a l, 1989; Baumeister et a l, 1996; Cole et a l, 1996). Colonic biopsies 
from patients with active IBD have shown a significantly increased level of 
Leukotriene B4 (LTB4) compared with biopsies from control patients. However, in 
those patients receiving steroids or 5-ASA products, LTB4 was markedly 
decreased. It has been postulated that drugs such as may potentially work by 
normalising levels of these pro-inflammatory substances (Schmidt et a l, 1995). 
Selective leukotriene inhibitors and receptor antagonists are currently under 
evaluation in the treatment of IBD (Roberts et a l, 1997). One of these, Zileuton, a 
5-lipoxygenase inhibitor has however been found to be only of very minimal 
benefit in IBD (Hawkey et a l, 1997). This suggests that although leukotrienes are 
important in IBD, they are only one of a large number of potential mechanisms 
that the immune system can employ to cause inflammation.
1.7.3.Thromboxanes.
The pro-inflammatory effects of thromboxanes are both direct (recruitment and 
activation of neutrophils, mucosal ulceration, reduction of suppressor T-cell 
activity) and indirect (vasoconstriction, platelet activation) (Rampton and Collins,
1993) Thromboxanes are produced in excess in CD in inflamed mucosa, non­
inflamed bowel and also by peripheral blood mononuclear cells (Rampton and 
Collins, 1993). It is possible that enhanced thromboxane production is important 
in IBD, because increased platelet aggregation and activation may be responsible 
for the microvascular infarction this has been proposed as an early pathogenic 
factor in CD (Soderholm et a l, 1999; Collins et a l, 1994). Selective thromboxane 
synthesis inhibitors and receptor antagonists such as picotamide and ridogrel are
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available for use in man and each has been found to be of limited value in IBD 
(Collins et al., 1994; Casellas et a l, 1995).
1.7.4 Platelet Activating Factor
The role of platelet activating factor (PAF) is not well understood and the 
evidence is somewhat contradictory. In two studies increased synthesis of PAF in 
the colorectal mucosa correlates well the degree of inflammation of patients with 
UC (Guimbaud et al., 1995; Wardle et al., 1996). However, other studies have 
found low concentrations of PAF in the rectal mucosa of patients with active UC 
compared with patients in remission or controls. This suggests that PAF is not an 
important inflammatory mediator in UC (Aimer et al., 1996). PAF stimulates 
mucosal chloride secretion in animal models and this suggests that it could 
contribute to the diarrhoea of UC (Bern et a l, 1989). The PAF receptor antagonist 
lexipafant shows some efficacy in treating inflammation in an animal model of 
acute colitis. This is demonstrated by a dose-dependent fall in macroscopic 
mucosal damage, neutrophil infiltration and reduced generation of inflammatory 
mediators (Meenan et al., 1996). However, there have been no published reports 
of trials of PAF antagonists in human IBD, and the importance of this mediator in 
the pathogenesis remains unclear.
1.7.5 Biologically Active Amines
Increased histamine secretion could contribute to vasodilatation, increased 
vascular permeability and increased fluid and electrolyte secretion in intestinal 
inflammation. Many years ago work describing increased rectal mucosal synthesis 
of histamine in patients with UC was published (Rampton et a l, 1980). More
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recent work has shown that histamine secretion has been found to be significantly 
increased in the inflamed mucosa of patients with CD and UC but not in 
unaffected tissue or in healthy controls. This would suggest that mast cell 
mediators like histamine could play a role in the pathogenesis of these diseases 
(Raithel et al., 1995), however no efficacy of antihistamines or any mast cell 
stabilising agents has ever been shown.
1.7.6 Reactive Oxygen Metabolites
In IBD there is an abundant infiltration of neutrophils into the mucosa. These cells 
in IBD have been recognised as the main source of potentially toxic molecules 
known as reactive oxygen metabolites (ROMs). Increased production of ROMs is 
found in inflamed tissue, isolated intestinal macrophages and peripheral blood 
monocytes from patients with IBD (Gross et al., 1994). Levels of endogenous 
antioxidants in patients with IBD, such as superoxide dismutase, were also found 
to be reduced (Salim, 1992). Indirect evidence of ROMs-mediated tissue damage 
comes from detection of lipid peroxidation in mucosal biopsies in active UC 
(Ahnfelt-Ronne et al., 1990). ROMs have a wide range of pro-inflammatory 
actions that are likely to contribute to the pathological appearances seen in IBD. 
There are reports of the beneficial effects of antioxidant agents such as superoxide 
dismutase (Emerit et al., 1989), allopurinol and dimethylsulphoxide (Salim, 1992) 
in IBD. Drugs such as aminosalicylates have had some of their anti-inflammatory 
actions ascribed to their ability to scavenge superoxide radicals directly or to 
inhibit the production of ROS in stimulated neutrophils (Allgayer et al., 1994).
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1.8.Nitric Oxide
1.8.1. Synthesis And Function Of Nitric Oxide
Nitric oxide (NO) is synthesised from the amino acid L-arginine by a family of 
enzymes referred to as the nitric oxide synthases (NOS). These enzymes assist in 
the oxidation of the amino acid L-arginine that in turn produces NO and 
L-citrulline. NO has a very short half-life and is broken down into other nitrogen 
oxides such as nitrite (NO2') and nitrate (NO3'), and in the presence of superoxide 
anion to the toxic metabolite peroxynitrite (ONOO‘) (Moncada and Higgs, 1993). 
Three isoforms of the enzyme NOS have so far been identified. Two of them are 
continuously present and are termed constitutive, endothelial NOS (eNOS) and 
neuronal (nNOS), while a third isoform is only expressed in areas of 
inflammation. Tissues express this isoform after induction by pro-inflammatory 
cytokines, microbes, and bacterial products. This isoform is called inducible nitric 
oxide synthase (iNOS) (Knowles and Moncada, 1994). All isoforms of NOS 
require various cofactors e.g. nicotinamide adenine dinucleotide (NADH) and 
tetrahydrobiopterine (BH4), but vary in their dependence on Ca2+ and calmodulin. 
Neuronal NOS, and endothelial NOS, which were cloned from rat cerebellum 
(Bredt et ah, 1991), bovine and human vascular endothelial cells (Lamas et ah, 
1992; Janssens et a l, 1992), respectively, are all constitutive enzymes and are 
calcium and calmodulin dependent. Neuronal NOS and endothelial NOS share 
-60% homology at the amino acid level. iNOS was originally cloned from murine 
macrophages and it is -50% homologous to endothelial NOS (Lowenstein et ah,
1992). Constitutive NOS produce small amounts of NO, (nM quantities), and are 
thought to be involved in homeostatic processes such as the tone of blood vessel 
vasculature (Moncada et a l, 1991). The inducible NOS is responsible for NO
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production in large quantities (pM quantities) and is highly regulated by cytokines 
(Moncada and Higgs, 1993; Morris, Jr. and Billiar, 1994). NO production 
synthesised by iNOS is delayed by several hours following stimulation, but once 
induced, is active for many hours. Human iNOS has been cloned and its expression 
and activity has been induced in a wide variety of cell types e.g. 
monocytes/macrophages (Reiling et a l , 1994), colonocytes (Sherman et a l , 1993), 
mesangial cells (Nicolson et a l , 1993), lung epithelial cells (Robbins et a l , 
1994;Asano et a l , 1994), hepatocytes (Geller et a l , 1993), astrocytes (Lee et a l ,
1993), chondrocytes (Palmer et a l , 1993) and smooth muscle cells (Junquero et a l ,
1992) when stimulated with a mixture of pro-inflammatory cytokines. The activity 
of iNOS is sensitive to inhibitors of DNA transcription and protein synthesis, e.g. 
actinomycin D and cycloheximide. Other substances such as glucocorticoids 
(Radomski et a l , 1990; Pfeilschifter, 1991) and cytokines such as TGFp, IL-4, 
LL-8 and IL-10 (Ding et a l , 1990; Cunha et a l , 1992; McCall et a l , 1992; 
Oswald et a l , 1992) have been found to inhibit iNOS activity in some cellular 
systems without affecting constitutive NOS.
Nitric oxide (NO) has both physiological and pathophysiological actions and is 
thought to have both anti-inflammatory and pro-inflammatory properties 
depending on the type and phase of the inflammatory reaction (Moncada et a l , 
1991; Whittle, 1995). For example, in the central nervous system NO acts as 
neurotransmitter and participates in functions such as long-term memory 
formation. A steady production of NO maintains the cerebral vasculature in a 
dilated state, thus regulating cerebral vascular tone.
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In the inflammatory reaction induction of NO synthesis is a key part of the host 
response. Induced NO can have a variety of effects depending on the amount, 
duration, and anatomic site of synthesis. This can be advantageous or harmful 
depending on various factors. NO is known to be responsible for mediation of 
macrophage cytotoxicity (Jorens et a l, 1995) and inhibition of platelet 
aggregation. This means it may contribute to certain disease states (Kuo and 
Schroeder, 1995; Moncada etal., 1991).
The effects of NO are widespread. Production of NO in large amounts can inhibit 
key enzymes by nitrosylation of reactive groups, such as iron-sulphur centres 
(Fe-S) and thiol groups (-SH), which are essential for enzyme catalytic function 
(Vedia et a l , 1992). NO can also inhibit enzymes in the mitochondrial electron 
transport chain and citric acid cycle, which may account for the cytotoxic and 
cytostatic effects of macrophage-derived NO on tumour cells and 
microorganisms. The cytotoxic activity of NO is thought to be due to the 
generation of more toxic radicals through its reaction with superoxide, forming 
peroxynitrite. This degrades to form hydroxyl radicals e.g. peroxynitrite 
(Beckman et al., 1990). This is considered a potent oxidant that reacts with 
proteins, lipids, and DNA, and it is a potent initiator of DNA strand breakage, 
which is an initiates the activation of the nuclear enzyme poly ADP ribosyl 
synthetase (PARS). Activation of this enzyme in turn leads to cell necrosis or 
apoptosis, and probably contributes to cellular injury in inflammation. (Szabo et 
a l , 1996).
1.8.2. The Role Of Nitric Oxide (NO) In Inflammatory Bowel Disease
Nitric oxide (NO) is produced at many sites in the gastrointestinal tract and it is
believed to act in pathological events (Whittle, 1994; Jorens et a l , 1995). The
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evidence, both in animal models and in human studies, indicates that NO is 
involved in gastrointestinal inflammation and has a role in the pathogenesis of 
IBD (Boughton-Smith, 1994). Recent studies have shown a marked increase in 
NO synthase activity in the inflamed mucosa from patients with active UC 
compared to non-inflamed tissue. Increased concentrations of citrulline, formed 
along with NO, were found in rectal biopsy specimens from patients with active 
UC than in those patients with quiescent disease or normal controls. In biopsy 
specimens incubated with the NOS inhibitor, L-NMMA, citrulline concentrations 
were significantly lowered (Middleton et al., 1993). Studies of the activity of both 
cNOS and iNOS in colonic mucosa and muscle tissue from patients with active 
UC and CD compared to control non-inflamed tissue revealed a substantial 
increase of Ca2+-independent NO synthase activity in UC, characteristic of iNOS 
activity. The iNOS activity in colonic mucosa of UC patients was substantially 
higher than in control mucosa. In CD patients, mucosal NOS activity did not 
differ from control values. There was no difference in NOS activity in colonic 
muscle between patients with UC and controls (Boughton-Smith et al., 1993). 
Measuring serum nitrate levels as an indirect measurement of NO production, it 
was found that NO production was increased in both active UC and CD (Oudkerk 
et al., 1995). In a different study rectal gas samples from patients with active UC 
was analysed using a chemiluminescence technique. NO concentrations were 
found to be more than 100 times higher in patients with active UC than in the 
controls (Lundberg et a l , 1994). Studies using another technique had similar 
results with increased luminal NO concentrations in patients with active UC but 
not in controls. This study revealed that a group of the UC patients were negative 
for NO. Further examination showed that these patients had blood visible in the
43
rectum and they suspected that NO, which is bound by haemoglobin, was 
therefore trapped in the lumen by the blood (Reynolds et a l , 1995). These results 
also suggest that the excess NO production in UC mainly occurs in very 
superficial mucosal layers (Lundberg et a l , 1994), because luminal NO 
measurements reflect NO production only in the superficial parts of the mucosa, 
because any NO production in deeper mucosal layers is probably bound by 
haemoglobin in blood vessels, and therefore does not reach the lumen.
1.8.3 Nitric Oxide Production By The Epithelial Cell
The exact cellular source of NO and iNOS in IBD has received little attention 
until recently (Alican and Kubes, 1996). Enhanced activity of the inducible form 
of nitric oxide synthase has been found in the mucosa of patients with UC, but not 
CD (Boughton-Smith et a l , 1993). Other studies using immunostaining and in 
situ hybridisation have demonstrated high expression of iNOS localised to the 
surface epithelium and crypts in the colonic mucosa from patients with UC 
(Godkin et a l, 1996; Rachmilewitz et a l, 1995a; McLaughlan et a l, 1997). 
Recently this enzyme was demonstrated to be exclusively synthesised in the 
colonic epithelial cells in patients with active IBD by two groups using 
immunostaining. There was no localisation of iNOS labelling to any cells in 
normal non-inflamed colon (Plate 1 reproduced with kind permission from Dr G 
Kolios) They have shown focal iNOS labelling localised to the epithelial cells in 
inflamed colonic mucosa in UC (Plate 2 reproduced with kind permission from Dr 
G Kolios), CD, and also in diverticulitis, suggesting that iNOS expression is a 
feature of intestinal inflammation. There was also a similar distribution of 
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Plate 1. A section from histologically normal human colon which has undergone 
immunohistochemistry to stain for inducible nitric oxide synthase. Any cells 
positive for iNOS are stained brown. The section shows that no cells stain brown 







Plate 2. A section of human colon from a patient with chronic ulcerative colitis 
which has undergone immunohistochemistry to stain for inducible nitric oxide 
synthase. Any cells positive for iNOS are stained brown. The section shows that 
the staining is exclusively located to the colonic epithelium. Magnification xlOO
There does seem to be a paradox when looking at NO production. This is, that a 
small quantity of NO is beneficial if not essential to normal physiological 
functioning, but that large quantities of NO appear to be damaging. The potential 
mechanisms of action for the protective effects of NO include maintenance of 
blood flow (Cattell and Cook, 1993), inhibition of platelet and leukocyte adhesion 
and/or aggregation within blood vessels, modulation of mast cell reactivity, and 
scavenging of reactive oxygen metabolites such as superoxide (Alican and Kubes,
1996). Excess NO produced by the inducible enzyme probably exacerbates the 
clinicopathological features of UC by direct cytotoxicity, activation of neutrophils 
(Schaefer et al., 1998), vasodilatation (Cohen et al., 1999; Tibballs, 1993) and 
interaction with superoxide to form the highly toxic peroxynitrite radical 
(Beckman et al., 1990; Kubes and Wallace, 1995). Endogenous NO produced in 
small quantities regulates mucosal barrier integrity and protects against the 
increase in mucosal permeability associated with acute inflammation. In 
experimental models, L-NAME protects against NO derived tissue injury and it 
was hoped this might be a potential new approach to treat IBD (Rachmilewitz et 
a l , 1995b).
The controlling mechanisms of iNOS production of NO by colonic epithelial cells 
have been studied by Dr Kolios in this group, here in Bath. Having established at 
the same time as Singer and his group that the epithelial cell was the principle site 
of iNOS production in the inflamed colon. (Plates 1 and 2) He then went on to 
describe how the combination of IL-la, IFN-y and TNF-a induces iNOS 
production in a colonic epithelial cell line. This was responsible for a large 
increase in NO production as measured by one of its metabolites, nitrite. This 
production could be inhibited by the T cell derived anti-inflammatory cytokines
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IL-4 and IL-13, but IL-10 had no effect on this system. (Kolios et al 1998). There 
is at present little understanding of how these findings in a cell line model relate 
to the complex interaction of epithelial cells and other cells in the mucosa in the 
inflamed colon.
N-(3-(Aminomethyl)benzyl)acetamidine, also known as 1400W, is a slow, tight 
binding inhibitor of human inducible nitric- oxide synthase (iNOS). Inhibition is 
dependent on the cofactor NADPH. 1400W in these experiments was shown to be 
at least 5000-fold more selective for iNOS versus eNOS. Thus, the potency and 
selectivity of 1400W inhibition of iNOS both in vitro and in vivo were far greater 
than of any previously described iNOS inhibitor. (Garvey et al., 1997) This has 
been shown to inhibit the increased production of nitric oxide as measured by 
nitrite by cytokine stimulated HT-29 cells (Dr S Weaver University of Bath. 
Personal communication of unpublished data).
1.9.Mechanism Of Action Of Therapeutic Agents
As well as knowing little if anything about the action of newer therapeutic agents 
e.g. IL-10, little is also known about how drugs that are used everyday in clinical 
practice, such as corticosteroids, act on the epithelial cell and influence the 
production of inflammatory mediators by the epithelial cells. Drugs such as 
steroids are known to have a wide variety of actions on the cellular functions that 
are likely to explain in part their mechanism of action. It is also apparent that the 
effects of steroids are widespread and act upon many components of the 
inflammatory process. These actions are known to include; altered lymphocyte 
and leukocyte trafficking, diminished adherence of leukocytes, diminished
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leukocyte chemotaxis, inhibition of phagocytosis by neutrophils, inhibition of 
release of arachidonic acid metabolites, kinins and cytokines,
Steroids are known to form a complex with an intracellular cytosolic receptor, 
which then translocates to the nucleus and affects DNA transciption and protein 
synthesis by a variety of different actions such as inducing ribonucleases. Steroids 
are also known to affect gene transcription by interacting with a variety of 
transciption factors e.g. NFkB or AP-1 (Barnes and Adcock, 1993; Brattsand and 
Linden, 1996; Ray et a l , 1995; Jonat et al., 1990). Pre-treatment with 
glucocorticoids are known to shorten the half-life of different mRNAs such as 
those of IL-ip, IL-2, and IL-6.(Tobler et al., 1992; Boumpas et a l , 1991a; 
Boumpas et a l , 1991 b)
Steroids are known to have potent effects on cytokine gene transcription. In many 
different cell systems then steroids are known to inhibit the production of IL-1, 
IL-2, IL-3, IL-4, IL-5, IL-6 IL-8 and TNF-a. (Barnes and Adcock, 1993) In 
colonoscopic biopsies from patients with active inflammatory bowel disease then 
dexamethasone has been shown to inhibit IL-1 and IL-6 (Mahida et a l , 1991b; 
Jones et a l , 1994)
The effect of steroids on NO production is much less clear. In many cell lines and 
cell types both animal and human, steroids do appear to be able to suppress iNOS 
e.g. the lungs (Yates et a l , 1995), rat mesangial cells (Pfeilschifter, 1991), Caco-2 
cells (Cavicchi and Whittle, 1999), rat peritoneal neutrophils (McCall et al., 1991) 
and RAW 264.7 cells (Walker et a l , 1997), although often at very large doses 
much higher than could ever be therapeutically obtained. Methylprednisolone has 
been found to decrease NO generation by cultured murine colonic mucosa 
although this has usually been achieved only in very high doses of
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methylprednisolone. It has been suggested that NO synthase activity is reduced 
during the culture with methylprednisolone and this steroid effect may relate to its 
therapeutic effect (Rachmilewitz et a l , 1995a). Inhibition of NO synthesis by an 
L-arginine analogue significantly ameliorated the extent of tissue injury in two 
models of experimental colitis (Rachmilewitz et al., 1995c). With the introduction 
of newer biological therapies such as IL-10 into clinical practice, this study sets 
out to examine the nature and site of action of these therapies.
To investigate the regulatory mechanisms involved in nitric oxide 
production in human colonic epithelial cells.
To explore the mechanisms by which steroids and the T-cell derived 
cytokines IL-4, IL-10 and IL-13 act on human colonic epithelial cells to 
change the expression of inflammatory mediators, such as chemokines 
and nitric oxide.
To explore the effects of steroids and T cell-derived cytokines on nitric 
oxide and chemokine production by human colonic epithelial cells co­
cultured with mononuclear cells
To characterise the relationship between human colonic epithelial cells 






Human recombinant IL -la This was a generous gift from Glaxo (Greenford, UK) 
and was diluted in sterile phosphate buffered saline (PBS) + 0.25% (w/v) bovine 
serum albumin (BSA, low endotoxin) (Sigma) and stored in aliquots at -70° C. It had 
a specific activity of 5x107 U/mg.
Human recombinant IL-4 This was purchased from Genzyme and stored in 
aliquots at -70° C. It had a specific activity > lxl07 U/mg
Human recombinant IL-10 This was kindly donated by Dr KW Moore (DNAX 
Palo Alto, California USA) and was diluted in sterile PBS + 0.1% (w/v) bovine 
serum albumin (BSA, low endotoxin) (Sigma) and stored in aliquots at -70° C. It had 
a specific activity lxlO7 U/mg.
Human recombinant IL-13 This was purified from culture supernatants of stable 
transfected CHO cells and generously provided by Dr A. Minty (Sanofi, Recherche, 
Labege, France) (Minty et a l , 1993). It was diluted in sterile PBS + 0.25% (w/v) 
bovine serum albumin (BSA, low endotoxin) (Sigma) and stored in aliquots at -70° 
C.
Human recombinant IFN-y This was purchased from Boehringer Mannheim, U.K 
and stored in aliquots at -70° C. It had a specific activity > 2.0x107 U/mg.
Human recombinant TNF-a This was a generous gifts from Bayer (Slough, UK) 
and was diluted in sterile PBS + 0.1% (w/v) bovine serum albumin (BSA, low
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ft 7endotoxin) (Sigma) and stored in aliquots at -70 C. It had a specific activity of 6x10 
U/mg.
Human recombinant EL-lra This was purchased from R&D Systems Europe Ltd, 
U.K and stored in aliquots at -70° C. It had a specific activity > 2.0x107 U/mg.
All cell culture plastics were purchased from Nunc.
2,3-DiaminonaphthaIene (DAN) was purchased from Lancaster Synthesis Ltd.
Sodium nitrite and Dimethyl-sulphoxide (DMSO) were purchased from Sigma 
Chemical, UK
Antibodies for IL-8 (anti-human IL-8 mouse monoclonal antibody, alkaline 
phosphatase conjugated anti-human IL-8 goat polyclonal antibody and human 
recombinant IL-8 standard) enzyme-linked immunosorbent assay (ELISA) were a 
generous gift from Dr I.J.D. Lindley (Sandoz Forschungsinstitut, Vienna, Austria) 
(Ceska et al., 1989).
2.2 Culture Conditions
2.2.1 HT-29 Colon Adenocarcinoma Cell Line
The human colon epithelial cell line HT-29 was obtained from the European 
Collection of Animal Cell Cultures (ECACC). The cells are adenocarcinoma grade 
II cells isolated from a primary tumour in a 44 year old Caucasian female (ECACC). 
They have characteristics of normal colonic epithelial cells such as epithelial
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polarity, presence of the actin-biding protein villin and the occurrence of enterocyte 
differentiation (Chantret et al., 1988).
2.2.2.Cell Culture
HT-29 cells were cultured in 80 cm2 tissue culture flasks in McCoy’s medium 
supplemented with penicillin (lOu/ml), streptomycin (lOpg/ml), fungizone 
(0.5pg/ml), and 10 % (v/v) foetal calf serum (FCS) referred to as complete 
medium. Cultures were then maintained at 37° C in an atmosphere of 5% CO2. 
The complete media was changed between 48 and 72 hours. When a confluent 
monolayer of HT-29 cells was present the medium was removed and the cells 
were washed 3 times with PBS without Ca2+ or Mg2+. Cells were then washed 
once with 3mis of a trypsin-EDTA mixture containing 0.05% (w/v) trypsin and 
0.02% (w/v) EDTA. Any excess solution was removed and the cells were 
incubated for approximately 5 minutes at 37° C and agitated gently until the cells 
had detached from the flask. The action of tiypsin/EDTA was inhibited by adding 
10ml of complete McCoy’s medium and the cell suspension was centrifuged at 
200g for 5 min. The cell pellet was resuspended in complete medium and cell 
counting and viability were checked using a Neubauer haematocytometer after 
mixing with Trypan Blue (Sigma). Any cells staining blue, due to the uptake of 
Trypan Blue were considered dead. Cell viability was always greater than 95%. 
Cells were counted and then seeded at 2-3 x 104/ml of McCoy’s complete 
medium, into 80 cm2 tissue culture flasks for further culture, or into 6-well plates 
for experimental protocols. Again media was exchanged after 48-72 hours until 
the HT-29 cells in the flasks and plates became confluent. This usually happened 
between 6-7 days after the cells were passaged.
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If the cells were being stored, cells were resuspended at a concentration of 4 x 106 
cells/ml in a medium containing 10% of dimethylsulphoxide (DMSO) (Sigma), 
40% FCS, and 50% McCoy’s medium. This cell suspension was then aliquoted 
into cryotubes (Nunc) at 1 ml / tube, gradually cooled in vapour phase of liquid 
nitrogen overnight and tubes were stored in liquid nitrogen. For resuscitation of 
cells from the liquid nitrogen, cells were rapidly defrosted at 37°C in a water bath, 
washed immediately in McCoy’s medium, re-suspended in complete medium and 
cells from 1 cryotube were seeded into 80 cm2 tissue culture flasks in McCoy’s 
medium, continuing as above.
When 6-well plates were confluent with HT- 29 cells, growth was arrested by 
changing the media to FCS-free McCoy’s medium and incubating for twenty-four 
hours. These growth-arrested cultures were then treated with fresh FCS-free 
McCoy’s medium and stimulated with the appropriate doses of either drugs, or 
cytokines, or vehicle controls for the times described in the results section. 
Supernatants were then collected, cellular debris removed by centrifuging the 
media and stored at -70° C until assayed for nitrite or chemokines. Cell counting 
and viability was routinely checked at the beginning and the end of the 
experiment, by microscopy and by trypan blue exclusion, using representative 
wells. Cell viability was always greater than 95%.
2.2.3. Colonic Biopsy Cultures 
Patient Selection
Multiple colonic biopsies were taken from the sigmoid colon in patients who 
underwent colonoscopy at the Royal United Hospital, Bath. These biopsies were 
approximately 2mm in diameter and weighed approximately 5-7mg. Patients used
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were divided into one of two different groups, dependent ultimately on the 
histological diagnosis reached by one of two experienced Consultant 
Histopathologists with a special interest in gastrointestinal pathology who were 
unaware of which patients were included in any experiments.
The patient groups were as follows:
1) Anyone with a new clinical diagnosis of ulcerative colitis who had yet to 
start on any treatment (n=17) (8 men and 9 women, mean age 44.9 years, range 16- 
81).
2) Anyone undergoing a colonoscopy for other reasons e.g. abdominal pain 
where the examination was found to be normal (n=22) (9 men and 13 women, mean 
age 51.3 years, range 24-84) (n=10)
A further group of patients was identified as those patients with distal ulcerative 
colitis with endoscopically normal mucosa in the proximal coloa Biopsies from this 
apparently normal area were studied in separate experiments if histological 
examination confirmed a normal appearance to histological examinatioa (n=8) (5 
males, 3 females, mean age 42.6 years, range 34-64)
Consent was obtained from patients in all cases and the local Research Ethics 
Committee granted approval for these studies.
2.2.4. Biopsy Culture
Human colonic biopsies were cultured using a method recently published by our 
group (Kolios et al., 2000). The biopsies were immediately placed in transport 
medium, Hanks’ balanced salts solution (HBSS) pH 7.4, supplemented with
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antibiotics (penicillin 100U/ml, streptomycin 100 fig/ml, gentamicin 50 jug/ml, 
and fungizone 2.5 pg/ml), transferred to the laboratory, and gently washed 3 times 
for 15 minutes in the transport medium. Mucosal biopsy specimens were then 
placed in a six-well plate (Gibco), containing 2 ml of TrowelTs-T8 65% (v/v) / 
RPMI-1640 25% (v/v) / foetal calf serum 10% (v/v) medium (supplemented with 
Hepes buffer 10 mM, glutamine 2 mM, penicillin lOOU/ml, streptomycin 100 
pg/ml, gentamicin 50 pg/ml, and fungizone 2.5 pg/ml) per well. Colonic biopsies 
were incubated at 37° C in an atmosphere of 5% CO2 in the presence of 
appropriate stimuli and were cultured for 30 hours. Supernatants were then 
collected for nitrite measurement and colonic specimens were used for total 
protein estimation of each well.
2.2.5. Co Culture Of HT-29 And Mixed Mononuclear Cells 
Mixed mononuclear cells (MMC) were isolated from blood from healthy human 
volunteers (n=4) using a standard protocol based on a method originally described 
by Boyum (Boyum, 1976). Briefly, for each subject a 50mls syringe was pre- 
heparinised with 250U of standard heparin. 50mls of blood was taken and diluted 
1:1 with RPMI 1640. Approximately 35mls of the mixture was then layered onto 
15mls of LymphoPrep (Nycomed, Oslo, Norway). This was then centrifuged for 
30 minutes with no brake and this gave a layer of mixed mononuclear cells. These 
were isolated and then washed three times in RPMI 1640. They were then 
resuspended in McCoy’s 5A media with 2% foetal calf serum supplemented with 
penicillin-streptomycin (lOU/ml and lOpg/ml) and fungizone (0.5pg/ml). Growth 
arrested HT-29 cells were co-cultured with 0.5 x 106 /ml of healthy MMCs.
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2.3. Fluorometric Nitrite Assay
Nitric oxide (NO) was determined by measuring the stable-end product, nitrite, in 
culture supernatants. Nitrite was measured using a fluorometric assay based upon 
the reaction of 2,3- Diaminonaphthalene (DAN) (Lancaster, Morecambe, UK) 
with nitrite under acidic conditions to form the fluorescent product 1-(H)- 
naphthotriazole. The assay was modified for use on a Photon Technology 
International (PTI) spectrofluorometer from the method of Misko et al (Misko et 
a l , 1993), which employed a 96 well plate format for a fluorescent plate reader. 
In contrast to the plate reader, the optimum excitation and emission wavelengths 
for the assay could be set on the fluorimeter, thus improving sensitivity. 
Fluorescent excitation and emission spectra for 1-(H)- naphthotriazole were 
obtained as previously described and optimum wavelengths were determined. An 
excitation wavelength of 365 nm and emission wavelength of 405 nm were found 
to be optimum, which was consistent with previous findings. A standard curve of 
sodium nitrite in McCoy’s medium ranging from 100 nM to 2 pM was prepared. 2 
ml of standard or culture supernatant was mixed in a bijou with 200 pi of freshly 
prepared DAN reagent (0.05 mg/ml DAN in 0.62 M HC1) and incubated at room 
temperature in the dark. After 10 minutes the reaction was stopped by the addition 
of 100 pi 2.8 N NaOH. Fluorescence intensity of 2 ml volumes of standards and 
samples was measured on the fluorimeter using an excitation wavelength of 365 
nm and an emission wavelength of 405 nm. Phenol red present in McCoy’s 
medium did not interfere with the assay. The lower limit of sensitivity of the assay 
was lOnM.
58
2.4. Enzyme-Linked Immunosorbent Assay (ELISA) For IL-8
Extracellular chemokine activity of culture supernatants was measured by double 
ligand ELISA. All ELISA samples were measured in duplicate using a well- 
established method (Brown et al, 1994). 96 well microtitre plates (Nunc Immuno 
Maxisorb) were coated with 100 pl/well of monoclonal anti-IL-8 antibody (5 
pg/ml) in carbonate coating buffer. Plates were covered and incubated overnight 
at 4° C. Plates were washed 3 x with wash buffer, followed by addition in 
duplicate of 100 pi IL-8 standard (0.05 to 2 ng/ml) or culture supernatant 
appropriately diluted in wash buffer + 2%  (v/v) FCS, and incubated for 2 hours at 
37° C. Plates were washed 3 x and 50 pi alkaline phosphatase-conjugated goat 
anti-IL-8 antibody (5 pg/ml) in wash buffer + 2%  FCS was added for 2 hours at 
37° C. Following 3 washes, plates were incubated with 100 pi of 1 mg/ml 
/7-nitrophenyl phosphate in warmed diethanolamine buffer at room temperature, 
until the top standard read ~ 1.5 OD. The reaction was terminated with 50 pi/ well 
of 3M NaOH, and the OD measured at 405nm. The assay was linear over a range 
between 0.2-2 ng/ml.
2.5. Protein Assay
To standardise for different size biopsies used in the studies the total protein of the 
biopsies was analysed. After 30 hours culture with appropriate stimuli culture 
supernatants removed for nitrite measurement and colonic biopsy specimens were 
used for estimation of protein content, using the Bio-Rad Protein microassay. The 
protein assay was based on the Bradford dye-binding procedure (Bradford, 1976). 
Known concentrations of bovine serum albumin (BSA) (Sigma) diluted in
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phosphate buffered saline (PBS), pH 7.4 were used as a standard curve. Colonic 
specimens were homogenised in PBS, pH 7.4, using an ultrasonic homogeniser 
and solubilised tissue was diluted in various dilutions (1:10-1:200). 200 pi of 
sample or standard and 50 pi of Bio-Rad protein Assay (Bio-Rad) were added per 




Total cellular RNA was isolated from HT-29 colon adenocarcinoma cells using 
RNAzol (Biogenesis Poole UK) according to the manufacturers instructions. 
Briefly the biopsies were homogenised in RNAzol (2ml per lOOmg tissue) 0.1ml 
of chloroform per 1 ml of homogenate was then added, the samples shaken 
vigorously for 15 seconds and then cooled on ice for 5 minutes. The suspension 
was then centrifuged for 15 minutes at 12,000g at 4°C. The homogenate then 
forms two phases: the lower blue phenol- chloroform phase and the colourless 
upper aqueous phase. The aqueous phase was then transferred to a separate 
eppendorf and an equal volume of isopropanol was added. The samples were then 
stored at 4°C for 15 minutes. The samples were then centrifuged at 12,000g for 15 
minutes at 4°C. RNA will then form a precipitate at the bottom of the tube. The 
supernatants were removed and RNA pellet washed in 1.5 ml 75 % ethanol 
solution. The pellet was then dried (but not completely) and then re-dissolved in 
RNase free water.
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2.6.2. Isolation Of mRNA
Then using a commercially available kit (QuickPrep Pharmacia) Poly (A) RNA was 
extracted from the above samples following manufacturers instructions. The 
supernatant was then mixed with oligo (dT) cellulose for three minutes. Following a 
further centrifugation, the pellet was washed with a high salt buffer (x5) followed by 
a low salt buffer (x2). It was then transferred to a microspin column from which the 
mRNA was eluted with the elution buffer. The mRNA was then precipitated with 
lOpl of glycogen solution and 40pi of potassium Acetate 1 ml of 95% ethanol The 
mRNA was then pelleted by centrifugation and then re-dissolved in water. mRNA 
was quantitated by measuring absorbance of 2 pi RNA in 1 ml 0.1 M NaOH at 
260 nm. The amount of RNA present in the samples (in pg) was calculated by:
A26o x dilution factor (500) x 40 x volume of remaining RNA solution in ml 
(0.048)
ODs were also read at 280 nm and 230 nm to assess the purity of RNA. A value 
of less than 2 for the OD26o • OD28o ratio indicated protein contamination. A low 
OD260 : OD23o ratio indicated guanidine contamination.
2.6.3 cDNA Generation Using Reverse Transcription PCR
Poly (A) RNA then underwent reverse transcription to generate cDNA Initially 5pl 
of the QuickPrep column elutate was diluted to a final volume of 12.5pl and 
denatured at 75°C for 3 minutes. The solution was then cooled at 4°C before the 
addition of 7.5pl of RT reaction mixture containing sufficient reagents for optimal 
concentration in 20pl. Random hexamers (Pd (N)6) at a final concentration of lpM, 
RT buffer xl, dNTPs each at 0.5mM, RNAsin at lU/pl and reverse transcriptase 
(superscript) at lp l  Reverse transcription was performed at 42 °C for 60 minutes
followed by a denaturation at 95°C for 2 minutes. The product was cooled on ice and 
underwent PCR immediately. To amplify ftagments of human iNOS, p Actin and 
IL-8 35 cycles of PCR were carried out using lOOng of cDNA as a template and 
oligo nucleotide primers corresponding to the genes being examined.
The primer sequence for Human iNOS was TGTGTCTTGGAAAGTCATCC and 
AATTCCACCAGTATGCAATG. This gave a product size for iNOS of 263 Kb. 
These primer sequences had been designed and selected using a commercially 
available program (Primer3 Output) so as to minimise primer dimerisation between 
pairs and with the selected house keeping gene (p actin) which served as an internal 
standard thus allowing semi-quantitative analysis between different samples.
The primer sequence for human IL-8 was TGGGTGCAGAGGGTTGTG and 
CAGACTAGGGTTGCCAGATTTA. This gave a product size for IL-8 of 562 Kb. 
The primer sequence for Human p actin was CTTTTCCAGCCTTCCTCC and 
GCAGTAATCTCCTTCTGCATC. This gave a product size for p-actin of 176 Kb. 
The primers were synthesised and supplied by PE Applied Biosystems UK 
(Warrington UK).
2.6.4 Separation Of PCR Products
PCR products to which 5 pi of 0.25% bromophenol blue and 15%Ficoll in water, 
were then run on a 2% agarose gel in 0.5x TBE at 100V to which ethidium bromide 
had been added. Bands were detected under UV light and compared to the lOObase 
pair ladder (Gibco). Co-amplification of both p actin and either IL-8 of iNOS were 
done on the same samples using a modification of a method previously described 
(Dr E Campbell and Dr M Watson, University of Bath. Personal communication) It 
had been demonstrated in earlier experiments that increasing amounts of RT product
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(0.3|il, 1.5pl and 3 pi) in the PCR reaction yielded differing amounts of final cDNA. 
This relationship could be demonstrated to be linear. Once above a certain amount of 
RT product then eventually a plateau in the amount of cDNA was produced. This 
highlighted the need to titrate each sample to allow accurate quantification. Product 
densities for p Actin, IL-8 and iNOS were linear in the range tested thus allowing 
cross sample comparison for IL-8 and iNOS relative to p-Actin. The ratio of PCR 
product, as measured by densitometry between IL-8 or iNOS and p actin at a 
constant volume of RT product (1.5pl was chosen), thus allowing standardisation of 
the target cDNA levels relative to those of the housekeeping gene and thus allowing 
cross sample comparison using the Mann Whitney U test.
2.7. Experimental Protocols
2.7.1.HT-29 Cells
HT-29 cells were seeded at 2-3 x 104/cm2 in six well plates and were maintained 
at 37° C in an atmosphere of 5% CO2 until confluent. Prior to stimulation with 
pro-inflammatory cytokines cells were pre-treated for two hours with doses of one 
of two steroids: prednisolone or budesonide (Sigma) from 30nM to 300pM. They 
were then treated with concentrations of IL-1 (lOng/ml), IFN-y (300U/ml) and 
TNF-a (lOOng/ml) in medium without the foetal calf serum and incubated for a 
period of 48 hours.
2.7.2. Colonic Biopsies
Multiple colonic biopsies were taken from the sigmoid colon in patients with newly 
diagnosed ulcerative colitis who underwent colonoscopy prior to the patient starting 
on any treatment. Paired biopsies were then incubated with one of two
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corticosteroids (prednisolone or budesonide) or one of three T cell derived cytokines 
(IL-4, IL-10 or IL-13) for 30 hours. Supernatant was removed and analysed for 
nitrite and IL-8. The biopsy material was analysed for protein content.
Similar biopsies were taken from the sigmoid colon in patients undergoing a 
colonoscopy for other reasons e.g. abdominal pain where the examination was found 
to be normal. Only those patients where the histology was reported as normal were 
included in the experiment. These biopsies were pre-treated with one of the two 
corticosteroids or one of three T cell derived cytokines for 2 hours. They were then 
stimulated with the combination of IL-1 (lOng/ml), IFN-y (300U/ml) and TNF-a 
(lOOng/ml) known to induce iNOS and IL-8 expression in HT-29 cells for a 
further 30 hours.
Further colonoscopic biopsies were taken from endoscopically normal areas in those 
patients with a new diagnosis of distal ulcerative colitis who had not yet been started 
on treatment. Only those patients where the histology was confirmed the endoscopic 
appearance of apparently normal mucosa were included in these experiments. These 
biopsies were pre-treated with either prednisolone or budesonide or one of the three 
T cell derived cytokines for 2 hours. They were then stimulated with the 
combination of IL-1 (lOng/ml), IFN-y (300U/ml) and TNF-a (lOOng/ml) known to 
induce iNOS and IL-8 expression in HT-29 cells for a further 30 hours.
2.8. Co-Culture Of Mixed Mononuclear Cells And HT-29 Cells
2.8.1. Examination Of A Variety Of Stimuli On The Co-Culture
To find appropriate stimuli that were able to induce NO production in a co-culture
but not in a single culture of either the HT-29 cells or the MMCs, the MMCs were
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stimulated both in isolation and also in a co-culture with the HT-29 cells. Nitrite 
was measured in the supernatant as a measure of NO production.
HT-29 cells were seeded at 2-3 x 104/cm2 in six well plates and were maintained 
at 37° C in an atmosphere of 5% CO2 until confluent. Once confluent these were 
co-cultured with MMCs isolated from normal volunteers as described above. The 
MMCs were at a concentration of 500,000/ml. A wide variety of stimuli were 
used either alone or in combination. Stimuli used included IL-1 (lOng/ml), IFN-y 
(300U/ml) and TNF-a (lOOng/ml) and Lipopolysaccharide (LPS) (5pg/ml). The 
aim of this experiment was to find the simplest stimulus which would induce a 
large rise in NO production in the co-culture but not be able to induce NO in 
either of the two cell types when cultured alone.
2.8.2 Effect Of Different Pre-Treatments On Stimulated Co-Cultures
Once the simplest combination of stimuli had been ascertained that would induce 
nitrite production in the co-culture the effect of either one of the corticosteroids or 
one of the T cell derived cytokines was examined. Different doses of these pre- 
treatments were introduced to the co-culture. After 2 hours the MMCs were 
stimulated to induce NO production. Supernatant was collected after a further 30 
hours and then analysed for nitrite.
2.8.3 Examination Of Conditioned Media From MMCs On HT-29 Cells
In separate experiments supernatant from stimulated MMCs (conditioned media) 
was removed after 6 hours and then the media was then centrifuged for 10 
minutes to allow the collection of cell free media. This cell free media was then
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transferred to confluent HT-29 cells in 6 well plates. After a further 24 hours the 
media was removed and analysed for nitrite.
2.8.4. Examination Of Site Of Action Of Different Pre-Treatments 
To examine the probable site of action of the steroids or the T cell derived 
cytokines on the stimulated co-cultures the following experiments were 
performed. Either the HT-29 cells or the MMCs were pre-treated for 2 hours with 
one of the steroids or one of the T-cell derived cytokines (IL-4, IL-10 or IL-13). 
The MMCs were then stimulated as previously described and the after a further 6 
hours the media was removed and centrifuged for 10 minutes to obtain a cell free 
media. This was then transferred to the confluent HT-29 cells. After a further 24 
hours the media was removed and underwent analysis for nitrite.
A further set of experiments was performed using interluekin-1 receptor 
antagonist (IL-lra). This was performed by pre-treating either the MMCs for 2 
hours prior to stimulation or by addition of the IL-lra to the conditioned media 
immediately prior to transfer to the HT-29 cells. The media was then removed 
after 24 hours and underwent analysis for nitrite.
2.9 Statistical Analysis
Duplicate determinations were performed in each experiment. The (n) number of 
each experiment is given in the respective figure legend. Data were analysed either 
by two-way analysis of variance (ANOVA) to determine if any statistical 
significance existed within the data groups or when using paired samples a Wilcoxon 
signed rank test was performed. ANOVA was followed by Dunnetfs test for the 
comparison of multiple groups to controls. This latter test identified which
treatments within the group were significantly different from the control Data were 
expressed as means ± SEM of (n) experiments. A probability value of p < 0.05 was 
taken as the criterion for a significant difference. Statistical anaylsis was done using 
SPSS for windows version 10.0.5
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2.10 Buffers And Solutions
2.10.1.Solutions And Reagents For Cell And Tissue Culture
Tissue culture reagents were used for cell and tissue cultures and all solution were
prepared using sterile, pyrogen-free distilled water (Steripak Ltd, Cheshire,UK).
Phosphate Buffered Saline (PBS), pH 7.4
140 mMNaCl 
2.7 mM KC1 
1.5 mM KH2HP04
8.1 mM Na2HP04
Hanks’ Balanced Salts Solutions (HBSS), pH 7.4 
100 ml 10X Hanks’ balanced salts (Gibco)
6 ml 7.5 sodium bicarbonate (Gibco)
20 ml 1M HEPES buffer solution (Gibco)
200 pi 40% (w/v) NaOH
Make up to 1L with distilled water. No need to pH.
McCoy’s medium 5A (Gibco)
Supplemented with penicillin (10u/ml, Gibco), streptomycin (10 pg/ml) (Gibco), 
and fungizone (0.5 pg/ml) (Gibco) before use.
Foetal Calf Serum (FCS)
FCS (Gibco) was heat-inactivated at 56° C for 30 minutes and stored at 20° C.
Trowell’s T8 / RPMI-1640 medium
65% Trowell’s T8 (Gibco)
25% RPMI-1640 (Gibco)
10% Foetal Calf Serum (FCS) (Gibco)
10 mM HEPES buffer solution (Gibco)
2 mM Glutamine (Gibco)
Supplemented with penicillin (lOU/ml) (Gibco), streptomycin (10 pg/ml) (Gibco), 
and fungizone (0.5 jig/ml) (Gibco) before use.
2.10.2. Solutions and buffers for Nitrite assay 
HC1 solution
0.62M HC1 in Milli-Q water.
NaOH solution
2.8N NaOH in Milli-Q water.
2.10.3. Solutions and buffers for ELIS As 











Adjust pH to 9.6 with IN HC1. Buffer can be kept for 2 weeks.
Diethanolamine substrate buffer, pH 9.8
10% (v/v) diethanolamine (BDH)
ImMMgCh
Store in the dark, at 4° C.
DEPC-treated water or buffer
Milli-Q water or buffer were treated with 1 ml of diethyl pyrocarbonate (DEPC, 
Sigma) per litre of water, and incubated overnight at 37° C. Autoclave (for 20 
minutes at 121° C).
0.5x TBE Stock (For 1 L)
Tris base 54g
Boric acid 27.5g




Effects Of Prednisolone and Budesonide on Inducible Nitric Oxide 
Synthase And IL-8 Expression in Colonic Epithelium
3.1 Effect Of Corticosteroids On Inducible Nitric Oxide Synthase (iNOS) And 
IL-8 Activity In Colonic Epithelial Cells
Growth arrested monolayers of HT-29 cells incubated for 48 hours in serum free 
media produce a small constitutive amount of nitrite. In these HT-29 cells, nitrite 
production increased from a basal level of 422 ±38 (control ± SEM) to 1068 ± 
158 pmoles/106 cells at 48 hours when stimulated with the three cytokines: IL-1 a  
(lOng/ml), IFN-y (300U/ml) and TNF-a (lOOng/ml). Pre-treatment with increasing 
concentrations of budesonide from lOnM to 300pM for two hours prior to 3 
cytokine stimulation only decreased nitrite production at very high concentrations 
of budesonide e.g. 30pM to 740 ± 82, 100 pM to 694 ± 88 and 300pM to 546 ± 
24 pmoles/106 cells. Pre-treatment with increasing concentrations of prednisolone 
from lOnM to 300pM for two hours at increasing concentrations of up to 300pM 
had no significant effect on nitrite production. Treatment of the HT-29 cells with 
either steroid alone did not significantly change the nitrite concentration in the 
supernatant. (Figure 1)
Growth arrested monolayers of HT-29 cells which had been incubated for 48 hours 
in serum free media produce a small constitutive amount of IL-8 production of 36.7 
± 0.1 ng/ml (control ± SEM). With three cytokine stimulation this rose to 472 ±
17.2 ng/ml. Pre-treatment with increasing concentrations of budesonide from 






2 8 a 800
3 2
I I  600 
I  i




Figure 1. Nitrite production by HT-29 colonic epithelial cells following stimulation for 48 hours 
incubation at 37° C with vehicle and the three cytokines IL -la  (lOng/ml), TNF-a (lOOng/ml), and 
IFN-y #300U/ml) added in combination (3C). Control is the amount of nitrite produced by HT-29 
cells in the absence of added cytokines. 300pM is the effect of 300pM of either of the two steroids 
added alone. A series of increasing doses (30nM-300pM) of the two steroids were used to pre-treat the 
HT-29 cells 2 hours prior to stimulation with the 3 cytokines. Nitrite levels were determined in 
supernatants, using a fluorescent substrate with a 10 nM level of detection. Each bar is the mean ± 
SEM of four experiments. No significant effect was found at any doses of the two steroids used.
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decreased IL-8 production again at very high concentrations of budesonide e.g. 
lOOpM to 264 ± 1 0  and 300pM to 251.2 ± 40 ng/ml. Pre-treatment with 
increasing concentrations of prednisolone from lOnM to 300pM for two hours 
prior to 3 cytokine stimulation had no significant effect on IL-8 production. 
Treatment with either steroid alone at a concentration of 300pM for 48 hours did 
not significantly change the IL-8 production by the HT-29 cells. (Figure 2)
3.2 Effect Of Corticosteroids On iNOS And IL-8 Activity By Colonic Biopsies
3.2.1. iNOS Activity In Colonic Biopsies From Inflamed Mucosa.
To examine why the two steroids have no effect on the colonic epithelial cell line 
yet obviously work in clinical practice the effect of the two steroids on NO and 
IL-8 production by paired colonic biopsies from patients with colitis. These were 
patients undergoing colonoscopy in which a new diagnosis of colitis was made. 
Prior to the biopsies being taken, patients had not been on any regular medication 
at all. Only patients who had inflammation consistent with colitis reported were 
included in the experiments.
Mucosal biopsy specimens of each patient were placed in four wells of a six well 
plate containing culture media with the appropriate stimuli per well. Two of the 
three wells were treated with 30nM of either prednisolone or budesonide. After 40 
hours total protein was estimated per well and the individual nitrite content of 
each well was measured and expressed as pmoles/lOOpg Protein. (Table 1)
At 40 hours baseline mean nitrite production per lOOug of protein in biopsies 
from inflamed areas in colitic patients (n=9)(M:F 6:3) was 1090 ± 351 
pmoles/lOOjig protein (mean ± SEM). With incubation of the biopsies with 
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Figure 2. IL-8 production by HT-29 colonic epithelial cells following stimulation for 48 hours 
incubation at 37° C with vehicle and the three cytokines IL-1 a  (lOng/ml), TNF-a (lOOng/ml), and 
IFN-y (300U/ml) added in combination (3C). Control is the IL-8 concentration produced by HT-29 
cells in the absence of added cytokines. 300)iM is the effect of 300pM of either of the two steroids 
added alone. A series of increasing doses (30nM-300pM) of the two steroids were used to pre-treat the 
HT-29 cells 2 hours prior to stimulation with the 3 cytokines. IL-8 levels were determined in 
supernatants, using an ELISA specific to IL-8. Each bar is the mean ± SEM of four experiments. The 
only significant effect was found at doses of budesonide of 100 and 300pM (p<0.05).
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biopsies were incubated with budesonide (30nM) production of nitrite fell to 313 
±104 pmoles/lOOpg protein. (p<0.05) (Figure 3)
Patient (No) Basal Prednisolone Budesonide
1 834 252 388
2 465 39 29
3 583 19 57
4 594 456 328
5 491 71 115
6 3655 51 15
7 1767 1116 905
8 1012 1425 695
9 403 15 283
Table 1. Nitrite production by cultures of human colonic mucosa from inflamed mucosa. Effect of 
incubation with 30nM o f either prednisolone or budesonide. All values expressed as pmoles/lOOpg 
protein
Paired biopsies from inflamed areas in the colon in patients with colitis were 
incubated with either prednisolone or budesonide for 40 hours. At the end of this 
period the mRNA from the biopsies was extracted and then using primers for both p 
actin and iNOS underwent PCR. This clearly showed that RNA for p actin and 
iNOS was present in the biopsies (Figures 4 and 5). To estimate the effect of the two 
steroids on the biopsies, the RNA underwent PCR with the two different primers at 
the same time. This allowed us to obtain a semi-quantitative measure of the effect of 
incubation with the two steroids. Levels for iNOS were compared to those for 
p-actin. This showed a significant fell in levels of iNOS when treated with either 
Prednisolone or Budesonide compared to levels in the untreated biopsies. Levels fell 
to 54.4% ±9.3% (p<0.05) when treated with prednisolone and 59.2% ±10.3% 
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Figure 3. Nitrite production by colonic biopsies taken from inflamed areas in patients (n=9) with 
colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of nitrite produced by 
the biopsies in 40 hours. Paired biopsies were also incubated with either prednisolone or budesonide at 
a concentration of 30nM. Nitrite levels were determined in supernatants, using a fluorescent substrate 
with a 10 nM level of detection. To correct for differing sizes of biopsies, the protein content of the 
biopsies was estimated using a protein assay. Nitrite levels are expressed as pmoles in the supernatant 
per lOOjigrams of protein. Each bar is the mean ± SEM of nine experiments. A significant effect was 
found at using this dose of the two steroids compared to control samples (p<0.05). There was no 
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Figure 4. p-actin expression in colonic biopsies from 7 patients with ulcerative colitis (A-G). Lower 
case letters indicate the matched negative control for each sample (a-g). The product size for P actin is 
178 Kbases (Kb). The gel shows fluorescence of ethidium bromide stained polymerase chain reaction 
products resolved by electrophoresis. Bands were detected under UV light and compared to the 100 
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Figure 5. iNOS expression in colonic biopsies from 6 patients with ulcerative colitis (A-F). Lower 
case letters indicate the matched negative control for each sample (a-f). The product size for iNOS of 
263 Kb. The gel shows fluorescence of ethidium bromide stained polymerase chain reaction products 
resolved by electrophoresis. Bands were detected under UV light and compared to the 100 Kb pair 




Figure 6. Mean densitometry readings (± SEM) for PCR product of iNOS 
expression measured as a percentage of maximum iNOS expression in the colitic 
mucosa. To obtain a semi-quantitative measurement of the effect of the two 
steroids on the biopsies, the RNA underwent PCR with the two different primers at 
the same time. This allowed us to obtain a semi-quantitative measure of the effect 
of incubation with the two steroids. Levels for iNOS were compared to those for p 
Actin. This showed a significant fall in levels of iNOS when treated with either 




P actin Marker -ve 3 1.5 0.3 -ve 3 1.5 0.3 -ve 3 1.5 0.3
Lane Colitic Mucosa Prednisolone treated Budesonide treated
Figure 7. Representative PCR blot o f three serial dilutions (3, 1.5 and 0.3 pi) o f mRNA from 
colonic mucosa from a single colitic patient duel probed for P-actin and iNOS. Each sample also 
has a negative control (-ve). The product size for iNOS o f263 Kb. The product size for P actin of 
176 Kb. The gel shows fluorescence of ethidium bromide stained polymerase chain reaction 
products resolved by electrophoresis. Bands were detected under UV light and compared to the 
100 Kb pair ladder in the first lane.
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3.2.2. IL-8 Activity in Colonic Biopsies From Inflamed Mucosa.
At 40 hours baseline IL-8 production per lOOug of protein in paired biopsies from 
inflamed areas in colitic patients (n=9) was 57.3 ± 14.8 ng/100 pg protein (mean ± 
SEM). With incubation with prednisolone the IL-8 production fell to 27.2 ± 9.7 
ng/lOOpg protein (p<0.05) and with budesonide production fell to 17.0 ± 4.2 
ng/lOOpg protein (p<0.05). (Table 2) (Figure 8)
Patient (No) .Basal Prednisolone Budesonide
1 46 2 10
2 55 86 35
3 158 6 18
4 85 63 19
5 25 16 13
6 64 26 14
7 56 31 40
8 14 12 1
9 13 4 7
Table 2. IL-8 production by cultures o f human colonic mucosa from inflamed mucosa: Effect of 
incubation with 30nM o f either prednisolone or budesonide. All values expressed as ng/lOOpg 
protein
Paired biopsies from inflamed areas in the colon in patients with colitis were 
incubated with either prednisolone or budesonide for 40 hours. At the end of this 
period the mRNA from the biopsies was extracted and then using primers for IL-8 
underwent PCR. This clearly showed that RNA for IL-8 was present in the biopsies 
(Figure 9). To estimate the effect of the two steroids on the biopsies the RNA 
underwent PCR with two different primers at the same time: p actin and IL-8. This 




Figure 8. IL-8 production by colonic biopsies taken from inflamed areas in patients (n=9) with colitis. 
The biopsies were incubated at 37° C for 40 hours. Control is the amount of IL-8 produced by the 
biopsies in 40 hours. Paired biopsies were also incubated with either prednisolone or budesonide at a 
concentration of 30nM. IL-8 levels were determined in supernatants, using an ELISA specific to IL-8. 
To correct for differing sizes of biopsies, the protein content of the biopsies was estimated using a 
protein assay. IL-8 levels are expressed as ng/ml in the supernatant per lOOpgrams of protein. Each 
bar is the mean ± SEM of nine experiments. A significant effect was found using this dose of the two 
steroids compared to control samples (p<0.05), although there was no difference between the two 
steroids at the dose studied.
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two steroids. Levels for IL-8 were compared to those for p Actin. This showed a 
significant M  in levels of IL-8 when treated with either Prednisolone or Budesonide 
compared to levels in the untreated biopsies. Levels fell to 43.2% ± 7.9% (p<0.05) 
when treated with prednisolone and 51.4% ± 3.0 % (p<0.05) (Figure 10). 
Representative blots from a patient are shown (Figure 11.)
3.2.3. iNOS Activity In Colonic Biopsies From Normal Colonic Mucosa.
To examine whether the cytokine stimulation produces NO production that is 
unable to be inhibited by prednisolone or budesonide, nitrite was measured in the 
supernatant from three cytokine stimulated colonic biopsies from patients without 
colitis. These were patients undergoing colonoscopy for abdominal pain or 
diarrhoea in which no inflammation was found. Any patients who had any 
inflammation reported were not included in the experiments.
Mucosal biopsy specimens of each patient were placed in four wells of a six well 
plate containing culture media with the appropriate stimuli per well. Two of the 
four wells were pre-treated for two hours with 30nM of either prednisolone or 
budesonide. After treatment, total protein was estimated per well and the 
individual nitrite content of each well was measured and expressed as 
pmoles/lOOpg Protein. (Table 3).
At 40 hours baseline mean nitrite production per lOOug of protein in non-inflamed 
biopsies from patients without colitis (n=12) (M:F 4:8) was 748 pmoles/100 pg 
protein. After stimulation with 3 cytokines the mean nitrite rose significantly to 
2935 (p<0.01.) Pre-treatment with prednisolone at 30nM significantly decreased 




Figure 10. Mean densitometry readings (± SEM) for PCR product of IL-8 expression measured as a 
percentage of maximum IL-8 expression in the colitic mucosa (n=4). To obtain a semi-quantitative 
measurement of the effect of the two steroids on the biopsies, the RNA underwent PCR with the two 
different primers at the same time. This allowed us to obtain a semi-quantitative measure of the effect of 
incubation with the two steroids. Levels for IL-8 were compared to those for p Actin. This showed a 
significant fall in levels of iNOS when treated with either Prednisolone or Budesonide compared to levels 




Figure 11. Representative PCR blot o f three serial dilutions (3, 1.5 and 0.3 pi) of mRNA from 
colonic mucosa from a single colitic patient duel probed for P-actin and IL-8. Each sample also 
has a negative control (-ve). The product size fey IL-8 of 562 Kb. The product size for p actin of 
176 Kb. The gel shows fluorescence of ethidium bromide stained polymerase chain reaction 
products resolved by electrophoresis. Bands were detected under UV light and compared to the 
100 Kb pair ladder in the first lane.
Marker -ve 3 1.5 0.3 -ve 3 1.5 0.3 -ve 3 1.5 0.3
Lane Colitic Mucosa Prednisolone treated Budesonide treated
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Pre-treatment with budesonide at 30nM decreased mean nitrite production to 2493 
pmoles/100 pg. (p<0.05) (Figure 12)





1 60 285 276 456
2 133 340 272 604
3 119 140 6 10
4 21 97 15 13
5 659 4275 3216 4081
6 374 6730 4115 4316
7 250 2196 763 605
8 126 852 895 901
9 421 1143 453 865
10 750 1130 399 362
11 667 2642 906 724
12 335 1962 938 237
Table 3. Nitrite production )y cultures o f human colonic mucosa from normal colon. Effect o1
pre-incubation with 30nM of either prednisolone or budesonide 2 hours prior to stimulation with a 
3 Cytokine mixture. All values expressed as pmoles/lOOjig protein
Paired biopsies from histologically normal areas in the colon in patients who 
underwent colonoscopy for reasons other than colitis were placed in four wells of a 
six well plate containing culture media with the appropriate stimuli per well. Two 
of the four wells were pre-treated for two hours with 30nM of either prednisolone 
or budesonide for 40 hours. At the end of this period the mRNA from the biopsies 
was extracted. To estimate the effect of the two steroids on the biopsies the RNA 
again underwent PCR with the primers for p actin and iNOS at the same time. This 
allowed us to obtain a semi-quantitative measure of the effect of incubation with the 
two steroids. Levels for iNOS were compared to those for p Actin.
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+ p<0.05 vs 3 cytokines
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Control 3 Cytokines 3C+ Prednisolone 3C+ Budesonide
Figure 12. Nitrite production by colonic biopsies taken from histologically normal areas in patients 
(n=12) without colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of 
nitrite produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three 
cytokines IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y ^ 300U/ml) added in combination (3C). 
Paired biopsies incubated with the three cytokines were also incubated with either prednisolone or 
budesonide at a concentration of 30nM for two hours prior to addition of the cytokines. Nitrite levels 
were determined in supernatants, using a fluorescent substrate with a 10 nM level of detection. To 
correct for differing sizes of biopsies, the protein content of the biopsies was estimated using a protein 
assay. Nitrite levels are expressed as pmoles in the supernatant per lOOpgrams of protein. Each bar is 
the mean of 12 different patients. A significant increase in nitrite production was found when treating 
the biopsies with the three cytokines compared to controls. (p<0.05). There was also a significant 
inhibition of cytokine stimulated nitrite production with pre-incubation of both budesonide and 
prednisolone (p<0.05).
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This showed a significant rise in the levels of iNOS in the three cytokine stimulated 
specimen compared to the control specimen from a level of 26.3± 11.3% to 100% of 
maximum activity. Levels fell to 44.7% ± 13.1% (p<0.05) when pre-treated with 
prednisolone and 52.4% ± 11.3% (p<0.05) when pre-treated with budesonide. 
(Figure 13) Representative blots from a patient are shown in figure 14.
3.2.4 IL-8 Activity in Colonic Biopsies From Normal Colonic Mucosa.
Paired colonic biopsies from patients without colitis were taken at the same time 
and stimulated with the same cytokine mixture. Supernatant was then removed at 
40 hours. At this time baseline IL-8 production per lOOug of protein in non­
inflamed biopsies from patients (n=12) (M:F 4:8) was 17.0 ± 2.7 ngml/lOOpg 
protein (control ± SEM). (table 4)






1 2 9 1 1
2 17 66 2 4
3 34 27 11 13
4 35 28 9 13
5 15 37 33 17
6 16 38 24 23
7 16 32 20 9
8 4 11 11 5
9 15 55 8 1
10 16 25 7 7
11 19 30 9 14
12 14 8 16 8
Table 4. IL-8 production by cultures o f human colonic mucosa from normal colon. Effect of 
pre-incubation with 30nM of either prednisolone or budesonide 2 hours prior to stimulation with a 
3 Cytokine mixture. All values expressed as ng/lOOpg protein
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+ p<0.05 vs control 
*p<0.05 vs 3C
Control Prednisolone Budesonide
Figure 13. Mean densitometry readings (± SEM) for PCR product of iNOS expression measured as a 
percentage of maximum iNOS expression in cytokine stimulated colonic mucosa. Biopsies were 
incubated with the three cytokines IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in 
combination (3C). Paired biopsies incubated with the three cytokines were pre-incubated with either 
prednisolone or budesonide at a concentration of 30nM for two hours prior to addition of the cytokines. 
To obtain a semi-quantitative measurement of the effect of the two steroids on the biopsies, the RNA 
underwent PCR with the two different primers at the same time. This allowed us to obtain a semi- 
quantitative measure of the effect of incubation with the two steroids. Levels for iNOS were compared to 
those for (5 Actin. This showed a significant rise in the level of iNOS from the unstimulated biopsies. 
There was also a fall in levels of iNOS when treated with either Prednisolone or Budesonide compared to 
levels in the cytokine stimulated biopsies (p<0.05).
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Marker Control -ve 3 1.5 0.3 -ve 3 1.5 0.3 -ve 3 1.5 0.3
Lane 3C stimulated 3C + prednisolone 3C +budesonide
Figure 14. Representative PCR biot o f three serial dilutions (3, 1.5 and 0.3 pi) of mRNA from 
colonic mucosa from a single subject duel probed for P-actin and iNOS. Biopsies were incubated 
with the three cytokines IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y(300U/ml) added in 
combination (3C). Paired samples were pre-treated with 30nM of either prednisolone or budesonide. 
Each sample also has a negative control (-ve). The product size for iNOS o f263 Kb. The product 
size for 2 actin of 176 Kb. The gel shows fluorescence of ethidium bromide stained polymerase 
chain reaction products resolved by electrophoresis. Bands were detected under LTV light and 
compared to the 100 Kb pair ladder in the first lane
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After stimulation with 3 cytokines this rose to 30.3 ±5.1 p<0.05. Pre-treatment 
with prednisolone at 30nM decreased IL-8 production to 12.6 ± 2.6 ng/100 pg 
protein (p<0.01). Pre-treatment with budesonide at 30nM decreased IL-8 
production to 9.5 ±1.9 ng/100 pg protein (p<0.01). (Figure 15)
3.2.5 iNOS Activity In Biopsies From Histologically Normal Colonic Mucosa in 
Patients with Colitis
To further examine whether cytokine stimulation produces NO production that is 
unable to be inhibited by prednisolone or budesonide, nitrite was measured in the 
supernatant from three cytokine stimulated colonic biopsies from non-inflamed 
areas of the colon in patients with colitis. (n=4) (M:F 2:2) These were patients 
undergoing colonoscopy for assessment of colitis in which there were areas that 
were macroscopically normal. Any patients who had inflammation reported in 
these biopsies were not included in these experiments.
Mucosal biopsy specimens of each patient were placed in four wells of a six well 
plate containing culture media with the appropriate stimuli per well. Two of the 
four wells were pre-treated for two hours with 30nM of either prednisolone or 
budesonide. After treatment, total protein was estimated per well and the 
individual nitrite content of each well was measured and expressed as 
pmoles/lOOpg Protein. (Table 5)
At 40 hours baseline nitrite production per lOOpg of protein in non-inflamed 
biopsies from patients with colitis was 497 ± 424 pmoles/100 pg protein (control 
± SEM). After stimulation with 3 cytokines this rose to 2219 ± 1074 pmoles/100 
pg protein (p<0.05). Pre-treatment with prednisolone at 30nM significantly 
decrease nitrite production which fell to 202 ±130 pmoles/100 pg protein
91
40 * p<0.05 vs control
+ p<0.05 vs 3C
Control 3C 3C+ Prednisolone 3C+ Budesonide
Figure 15. IL-8 production by colonic biopsies taken from histologically normal areas in patients 
(n=12) without colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of 
nitrite produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three 
cytokines IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in combination (3C). 
Paired biopsies pre-treated with either prednisolone or budesonide at a concentration of 30nM for two 
hours were also incubated with the three cytokines. IL-8 levels were determined in supernatants, using 
an ELISA specific to IL-8. To correct for differing sizes of biopsies, the protein content of the biopsies 
was estimated using a protein assay. IL-8 levels are expressed as ng/ml in the supernatant per 
lOOpgrams of protein. Each bar is the mean ± SEM of 12 different patients. A significant increase in 
IL-8 production was found when treating the biopsies with the three cytokines compared to controls 
(p<0.05). A significant inhibition of this effect using the dose of either the two steroids studied 
compared to the cytokine stimulated samples was also noted (p<0.05).
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(p<0.01). Pre-treatment with budesonide at 30nM significantly decreased nitrite 
production to 260 ± 54 pmoles/100 pg. (p<0.01) (Figure 16)





1 920 3294 332 314
2 73 1145 72 54
3 238 1972 162 290
4 758 2466 244 228
Table 5. Nitrite production by cultures of macroscopically normal human colonic mucosa from 
patients with colitis. Effect o f pre-incubation with 30nM o f either prednisolone or budesonide 2 
hours prior to stimulation with a 3 Cytokine mixture. All values expressed as pmoles/lOOpg 
protein
3.2.6.IL-8 Activity In Biopsies From Histologically Normal Colonic Mucosa in 
Patients with Colitis
At 40 hours baseline IL-8 production per lOOpg of protein in non-inflamed 
biopsies from patients with colitis was 12.6 ±1.8  ng/100 pg protein (control ±
SEM). After stimulation with 3 cytokines this rose to 32.0 ± 7.3 ng/lOOpg protein 
(p<0.05). Pre-treatment with prednisolone at 30nM significantly decreased IL-8 
production which fell to 7.4 ± 2.9 ng/100 pg protein (p<0.01).






1 13 20 3 4
2 11 36 6 9
3 10 28 8 6
4 16 44 13 17
Table 6. IL-8 production by cultures of macroscopically normal human co onic mucosa from
patients with colitis. Effect of pre-incubation with 30nM of either prednisolone or budesonide 2 
hours prior to stimulation with a 3 Cytokine mixture. All values expressed as ng/100|ig protein.
Pre-treatment with budesonide at 30nM significantly decreased IL-8 production to
















Control 3 Cytokines 3C+ Prednisolone 3C+Budesonide
Figure 16. Nitrite production by colonic biopsies taken from histologically normal areas in patients 
(n=4) with colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of nitrite 
produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three cytokines IL- 
l a  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in combination (3C). Paired biopsies 
incubated with the three cytokines were also incubated with either prednisolone or budesonide at a 
concentration of 30nM for two hours prior to addition of the cytokines. Nitrite levels were determined 
in supernatants, using a fluorescent substrate with a 10 nM level of detection. To correct for differing 
sizes of biopsies, the protein content of the biopsies was estimated using a protein assay. Nitrite levels 
are expressed as pmoles in the supernatant per lOOpgrams of protein. Each bar is the mean ± SEM of 
4 different patients. A significant increase in nitrite production was found when treating the biopsies 
with the three cytokines compared to controls (p<0.05). A significant inhibitory effect of pre-treatment 
with either of the two steroids of the cytokine stimulated samples was noted (p<0.05). There was no 




Control 3 C 3C+ Prednisolone 3C+ Budesonide
Figure 17. IL-8 production by colonic biopsies taken from histologically normal areas in patients 
(n=4) with colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of IL-8 
produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three cytokines IL- 
l a  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in combination (3C). Paired biopsies 
incubated with the three cytokines were also incubated with either prednisolone or budesonide at a 
concentration of 30nM for two hours prior to addition of the cytokines. DL-8 levels were determined in 
supernatants, using an ELISA specific to IL-8. To correct for differing sizes of biopsies, the protein 
content of the biopsies was estimated using a protein assay. IL-8 levels are expressed as ng/ml in the 
supernatant per lOOpgrams of protein. Each bar is the mean ± SEM of 4 different patients. A 
significant increase in IL-8 production was found when treating the biopsies with the three cytokines 
compared to controls (p<0.05). A significant inhibitory effect of pre-treatment with either of the two 
steroids of the cytokine stimulated samples was noted (p<0.05). There was no significant difference 
between the two steroids at the dose studied.
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3.3 Discussion and Technical Points
In the colonic epithelial cell line model (HT-29) the production of both IL-8 and 
NO as measured by nitrite are essentially unaffected by a wide dose of steroids 
ranging from lOnM to 300mM. Any reduction in NO production and IL-8 
production only occurs at doses that far exceed any concentrations that could be 
achieved in treatment doses, for example lOOpM or above. This is in contrast to 
the experience of workers who have used steroids on other cell types and found 
that iNOS transcription can be inhibited. In these studies workers have shown that 
in some cell types e.g.Caco-2 and RAW 264.7 cells that transcription of iNOS can 
be inhibited by incubation with steroids (Walker et al., 1997; Cavicchi and 
Whittle, 1999). The evidence to date suggests that both IL-8 and NO are 
important in the pathophysiology of inflammatory bowel disease and as we know 
that both prednisolone and budesonide are important clinically in the management 
of colitis then another explanation appeared likely. There were several 
possibilities. Firstly, was NO or IL-8 production by colonic epithelial cells 
unaffected by steroids? Secondly, was the method of stimulating HT-29 cells with 
IL-la, IFN-y and TNF-a to produce NO and IL-8, effectively steroid resistant? 
Thirdly, was there another cell type that acted directly upon the colonic epithelial 
cell which was sensitive to steroids? Lastly, was the HT-29 cell so different to the 
normal colonic epithelial cell that it was immune to the effect of steroids?
The results of the experiment looking at biopsies from patients with active 
inflammation show clearly that NO production and IL-8 production is 
dramatically reduced when incubated with very low doses of both the steroids 
studied (30nM) i.e. 1000 times less dose than that which had an effect on the 
cytokine stimulated HT-29 cells. This would suggest that the evidence that
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steroids when used for the management of IBD reduces inflammation at least in 
part by reducing IL-8 and nitrite production. One of the interesting differences in 
this study compared with other studies is that all of these patients are newly 
diagnosed colitic patients who are on no treatment prior to the experiment. Other 
studies looking at immunohistochemistry and other changes in NO biochemistry 
have used patients who are already well established on treatment often including 
steroids.
This effect of the steroids was also confirmed by the data from the PCR results 
looking at iNOS and IL-8 mRNA. This first experiment shows that mRNA for 
iNOS is produced in colitis and that the levels of the mRNA are reduced when the 
inflamed biopsies were incubated with either prednisolone or budesonide. 
Although the method used of dual probing is only semi-quantitative the evidence 
combined with the nitrite and IL-8 data from the incubated biopsies from inflamed 
colonic biopsies would strongly suggest that this is a real reduction in iNOS and 
IL-8 production by down regulation of mRNA. Ideally, northern blot techniques 
would have been used, and in fact that this was tried on several occasions. 
Unfortunately, even after 20 hours of incubation too much degradation of the 
mRNA had occurred and this did not allow us to proceed with this method of 
examining how much mRNA was present. Also results from Western blot analysis 
would have been presented to confirm a lowering of the product of the iNOS 
gene. Unfortunately within the time restraints allowed to do the work in, I was 
unable to do this.
As the response of histologically normal biopsies to the same cytokine stimulation 
used in the HT-29 cell model is markedly different, a further set of experiments 
was performed. Three specific queries were addressed. Firstly, whether the
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cytokines were able to stimulate the biopsies to produce nitric oxide via 
stimulation of iNOS? Secondly, whether the cytokines were creating conditions 
where steroids were unable to act upon the epithelial cells? We know from the 
previous work from Singer and Kolios that iNOS is almost exclusively produced 
in colitis by colonic epithelial cells. Therefore any changes in iNOS are thought to 
be due to effects on the colonic epithelium. Thirdly was there any difference in 
responses between histologically normal biopsies in patients with or without 
colitis?
These experiments showed that normal mucosa when exposed to IL-la, TNF-a 
and IFN-y produces large quantities of both IL-8 and NO as measured by nitrite. 
In both colitic and non-colitic patients, both nitrite and IL-8 are suppressed in 
histologically normal when pre-treated with steroids prior to stimulation. The 
levels of iNOS mRNA as measured by PCR does indeed fall when pre-treated 
with either one of the two steroids prior to stimulation with the three cytokines. 
This suggests that teanscription of iNOS mRNA is inhibited by the steroids and 
that this is in part at least the mechanism in reduction of nitrite levels. This 
similarity between inflamed mucosa and stimulated mucosa would suggest that 
the site of action of the steroids is similar, and that the steroids are able to prevent 
the stimulatory factors acting upon the colonic epithelial cells. It is not clear 
whether the stimulatory cytokines act directly upon the epithelial cell to induce 
the transciption of iNOS, but it is likely that they act here and upon other cells in 
the colonic mucosa e.g. Intraepithelial lymphocytes. The effect of the steroids is 
not as marked as in the inflamed mucosa alone but this may be due to a variety of 
factors such as maximal stimulation in the cytokine model which may not be the 
case in the inflamed mucosa or that the combination of cytokines used to
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Effects Of IL-4. IL-10 and IL-13 on Inducible Nitric Oxide 
Expression in Colonic Epithelial Cells
4.1 Effect Of Incubation With IL-4, IL-10 Or IL-13 On Inducible Nitric Oxide 
Synthase (iNOS) And IL-8 Activity In Colonic Biopsies
4.1.1. iNOS Activity In Colonic Biopsies From Inflamed Mucosa.
To examine the effects of the three T cell derived cytokines IL-4, IL-10 and IL-13 
have on colonic biopsies a series of experiments were designed. The effect of 
IL-4, IL-10 or IL-13 has on NO and IL-8 production by colonic biopsies was 
examined in paired colonic biopsies from patients with colitis. These were 
patients undergoing colonoscopy in which a new diagnosis of colitis was found. 
Only patients who had inflammation consistent with ulcerative colitis reported 
were included in the experiments.
Mucosal biopsy specimens of each patient were placed in five wells of a six well 
plate containing culture media with the appropriate stimuli per well. Three of the 
five wells were treated with 30ng/ml of IL-4, IL-10 or IL-13. After 40 hours total 
protein was estimated per well and the individual nitrite content of each well was 
measured and expressed as pmoles/lOOpg Protein. (Table 7)
At 40 hours baseline mean nitrite production per lOOug of protein in biopsies 
from inflamed areas in colitic patients (n=8)(M:F 6:3) was 1427 pmoles/100 pg 
protein. Incubation with IL-10 mean nitrite levels fell to 475 pmoles/lOOpg 
protein (p<0.05). Incubation with IL-4 mean nitrite levels fell to 901 which was
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non-significant and with IL-13 mean nitrite was measured at 1433 pmoles/lOOpg 
protein. (Figure 18)
Patient No Basal IL-4 IL-10 IL-13
1
1410 2692 138 682
2
1346 408 450 224
3
1586 744 556 684
4
1016 480 280 348
5
342 738 112 1146
6
1882 1174 454 6600
7
1240 262 208 354
8
2600 710 1603 1426
Table 7. Nitrite production by cultures of human colonic mucosa from inflamed mucosa. Effect of
incubation with 30ng/ml o f IL-4, IL-10 or IL-13. All values expressed as pmoles/lOOpg protein
Further paired biopsies from inflamed areas in the colon in patients with colitis were 
incubated with IL-4, IL-10 or IL-13 for 40 hours. At the end of this period the 
mRNA from the biopsies was extracted and then the mRNA underwent PCR using 
primers for iNOS and p actin. To estimate the effect of the anti-inflammatory 
cytokines on the biopsies, the RNA underwent PCR with the two different primers at 
the same time. This allowed us to obtain a semi-quantitative measure of the effect of 
incubation with the two IL-4, IL-10 or EL-13. Levels for iNOS were compared to 
those for p Actin. This showed a significant fell in levels of iNOS when treated with
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Figure 18. Nitrite production by colonic biopsies taken from inflamed areas in patients (n=8) with 
colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of nitrite produced by 
the biopsies in 40 hours. Paired biopsies were also incubated with IL-4, IL-10 or IL-13 at a 
concentration of 30ng/ml. Nitrite levels were determined in supernatants, using a fluorescent substrate 
with a 10 nM level of detection. To correct for differing sizes of biopsies, the protein content of the 
biopsies was estimated using a protein assay. Nitrite levels are expressed as pmoles in the supernatant 
per lOOpgrams of protein. Each bar is the mean of eight experiments. A significant effect was found 
using this dose of IL-10 compared to control samples (p<0.05). There was no significant difference 
between either IL-4 or IL-13 and the control biopsies studied.
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either IL-4, IL-10 or IL-13 compared to levels in the untreated biopsies. Levels fell 
to 60.3% ± 2.0% (p<0.05) when treated with IL-4 (p<0.05), 25.1 ± 8.3% when 
treated with IL-10 (p<0.01) and 78.2% ± 16.8% when treated with IL-13 (not 
significant) (figure 19). Representative blots from a patient are shown (figure 20).
4.1.2. IL-8 Activity In Colonic Biopsies From Inflamed Mucosa 
At 40 hours baseline IL-8 production per lOOug of protein in biopsies from 
inflamed areas in colitic patients was 64 ± 9 ng/100 pg protein (control ± SEM). 
With incubation with IL-4 this fell to 27 ± 6 ng/100 pg protein (p<0.05) and with 
IL-10 this fell to 35 ± 7 ng/lOOpg protein (p<0.05). With incubation with IL-13 
there was no significant difference with IL-8 levels of 64 ± 28 ng/lOOpg protein 
(Table 8) (Figure 21)
Patient (No) Basal IL-4 IL-10 IL-13
1 105 48 47 42
2 34 14 13 37
3 59 34 16 18
4 87 8 60 8
5 73 56 55 38
6 34 15 7 46
7 46 28 45 255
8 78 14 36 71
Table 8. IL-8 production by cultures of human colonic mucosa from inflamed mucosa: Effect of 
incubation with 30ng/ml o f  IL-4, IL-10 or IL-13. All values expressed as ng/lOOpg protein
Further paired biopsies from inflamed areas in the colon in patients with colitis were 




Figure 19. Mean densitometry readings (+ SEM) for PCR product of iNOS expression measured 
as a percentage of maximum iNOS expression in the cytokine stimulated (3C) colonic mucosa 
(n=4). To obtain a semi-quantitative measurement of the effect of the cytokines on the biopsies, the 
RNA underwent PCR with the two different primers at the same time. This allowed us to obtain a 
semi-quantitative measure of the effect of incubation with the cytokines. Levels for iNOS were 
compared to those for p Actin. There was a significant rise in the levels of iNOS mRNA in the 
cytokine stimulated mucosa compared to the unstimulated normal mucosa (p<0.05). There was a 
significant fall in levels of iNOS when treated with IL-4 or IL-10 to levels in the untreated colitic 






Marker 3 1.5 0.3 3 1.5 0.3 3 1.5 0.3 Marker 3 1.5 0.3 3 1.5 0.3
Lane -ve Colitic -ve IL-4 -ve IL-10 Lane -ve Colitic -ve IL-13
treated treated treated treated
Figure 20. Representative PCR blot of three serial dilutions (3, 1.5 and 0.3 pi) of mRNA from 
colonic mucosa from a single colitic patient duel probed for P-actin and iNOS. Each sample also 
has a negative control (-ve). The product size for iNOS o f263 Kb. The product size for 2 actin of 176 
Kb. The gel shows fluorescence of ethidium bromide stained polymerase chain reaction products 
resolved by electrophoresis. Bands were detected under UV light and compared to the 100 Kb pair 
ladder in the first lane.
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Figure 21. IL-8 production by colonic biopsies taken from inflamed areas in patients (n=8) with 
colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of IL-8 produced by 
the biopsies in 40 hours. Paired biopsies were also incubated with IL-4, IL-10 or IL-13 at a 
concentration of 30ng/ml. IL-8 levels were determined in supernatants, using an ELISA specific to 
IL-8. To correct for differing sizes of biopsies, the protein content of the biopsies was estimated using 
a protein assay. IL-8 levels are expressed as ng/ml in the supernatant per lOOpgrams of protein. Each 
bar is the mean ± SEM of eight experiments. A significant effect was found using this dose of both 
IL-4 and IL-10 compared to control samples (p<0.05). There was no significant difference between 
IL-13 and the control biopsies. There was no significant difference between IL-4 and IL-10 at the dose 
studied.
mRNA from the biopsies was extracted and then using primers for IL-8 and p actin 
underwent PCR. To estimate the effect of the T-cell derived cytokines on the 
biopsies the RNA underwent PCR with the two different primers at the same time. 
This allowed us to obtain a semi-quantitative measure of the effect of incubation 
with the IL-4, IL-10 or IL-13. Levels for IL-8 were compared to those for p Actin. 
This showed a significant fell in levels of IL-8 when treated with either IL-4, IL-10 
or IL-13 compared to levels in the untreated biopsies. Levels fell to 50.4% ± 5.7% 
(p<0.05) when treated with IL-4 (p<0.05), 24.9 ± 14.7% when treated with IL-10 
(p<0.01) and 75.1% ± 21.6% when treated with IL-13 (not significant) (Figure 22). 
Representative blots from a patient are shown (Figure 23)
4.1.3 iNOS Activity In Colonic Biopsies From Normal Colonic Mucosa.
To examine whether the cytokine stimulation in the HT-29 cells induces NO
production that is unable to be inhibited by IL-10, nitrite was measured in the
supernatant from three cytokine stimulated colonic biopsies from patients without
colitis. These were patients undergoing colonoscopy for abdominal pain or
diarrhoea in which no inflammation was found. Any patients who had any
inflammation reported in the endoscopically normal biopsies were not included in
the experiments.
Mucosal biopsy specimens of each patient were placed in five wells of a six well 
plate containing culture media with the appropriate stimuli per well. Each of the 
five wells were pre-treated for two hours with 30ng/ml of either IL-4, IL-10 or 
IL-13. After treatment, total protein was estimated per well and the individual 
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Figure 22. Mean densitometry readings (± SEM) for PCR product of IL-8 expression measured 
as a percentage of maximum IL-8 expression in the colitic mucosa. To obtain a semi-quantitative 
measurement of the effect of the cytokines on the biopsies, the RNA underwent PCR with the two 
different primers at the same time. This allowed a semi-quantitative measure of the effect of 
incubation with the cytokines studied. Levels for IL-8 were compared to those for P Actin. This 
showed a significant fall in levels of iNOS when treated with either IL-4 or IL-10 compared to levels 
in the untreated biopsies (p<0.05). There was no effect found of IL-13 at the dose studied.
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Lane -ve Colitic -ve IL-4 -ve IL-10 Lane -ve Colitic -ve IL-13
treated treated treated treated
Figure 23. Representative PCR blot of three serial dilutions (3, 1.5 and 0.3 pi) of mRNA from 
colonic mucosa from a single colitic patient duel probed for P-actin and IL-8 . Each sample also 
has a negative control (-ve). The product size for IL-8 of 562 Kb. The product size for 2 actin of 
176 Kb. The gel shows fluorescence of ethidium bromide stained polymerase chain reaction 
products resolved by electrophoresis. Bands were detected under UV light and compared to the 







1 277 944 191 23 99
2 65 395 117 99 50
3 472 934 19 12 18
4 136 283 69 11 132
5 470 1642 432 636 754
6 494 1487 843 765 225
7 303 699 115 497 1574
8 376 545 366 297 154
9 468 947 348 385 248
10 16 169 13 15 30
Table 9. Nitrite production by cultures o f human colonic mucosa from normal colon. Effect of 
pre-incubation with 30ng/ml o f IL-4, IL-10 or IL-13 2 hours prior to stimulation with a 3 Cytokine 
mixture. All values expressed as pmoles/lOOpg protein
At 40 hours baseline nitrite production per lOOug of protein in non-inflamed 
biopsies from patients without colitis was 615 ± 114 pmoles/100 pg protein 
(control ± SEM). After stimulation with 3 cytokines this rose to 1609 ± 308 
(p<0.05). Pre-treatment with all three cytokines at 30 ng/ml produced a significant 
fall in nitrite production. IL-4 to 502 ± 162 pmoles/100 pg protein (p<0.01). IL-10 
to 548 ± 180 (p<0.05), and IL-13 to 656 ± 308 (p<0.05). (Figure 24)
4.1.4 IL-8 Activity In Colonic Biopsies From Normal Colonic Mucosa.
Paired colonic biopsies from patients without colitis were taken at the same time 
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Figure 24. Nitrite production by colonic biopsies taken from histologically normal areas in patients 
(n=8) without colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of 
nitrite produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three 
cytokines IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y A300U/ml) added in combination (3C). 
Paired biopsies incubated with the three cytokines were also incubated with IL-4, IL-10 or IL-13 at a 
concentration of 30ng/ml for two hours prior to addition of the cytokines. Nitrite levels were 
determined in supernatants, using a fluorescent substrate with a 10 nM level of detection. To correct 
for differing sizes of biopsies, the protein content of the biopsies was estimated using a protein assay. 
Nitrite levels are expressed as pmoles in the supernatant per lOOpgrams of protein. Each bar is the 
mean ± SEM of eight different patients. A significant increase in nitrite production was found when 
treating the biopsies with the three cytokines compared to controls. (p<0.05). A significant inhibition 
of this effect using the dose of all three anti-inflammatory cytokines studied compared to the cytokine 








1 15 25 13 10 12
2 5 13 9 11 13
3 4 7 1 1 1
4 3 10 9 7 7
5 4 37 6 16 23
6 22 46 35 15 12
7 18 58 26 24 80
8 32 48 18 2 14
9 3 17 3 2 2
10 17 94 33 54 110
Table 10. IL-8 production by cultures of human colonic mucosa from normal colon. Effect o f  
pre-incubation with 30ng/ml o f 11-4, IL-10 or IL-13 2 hours prior to stimulation with a 3 Cytokine 
mixture. All values expressed as ng/100pg protein
At 40 hours baseline IL-8 production per lOOug of protein in non-inflamed 
biopsies from patients without colitis was 12 ± 3.2 ng/100 pg protein (control ± 
SEM). After stimulation with 3 cytokines this rose to 36 ± 8.6 ng/lOOpg protein 
p<0.05. Pre-treatment with IL-4 produced a significant fall in IL-8 production to 
15 ± 3.5 ng/100 pg protein (p<0.05) and IL-10 led to a fall to 14 ± 4.9 ng/lOOpg 
protein (p<0.05). Pre-treatment with IL-13 did not lead to a significant fall 27 ± 
11.6 ng/lOOpg protein (not significant). (Table 10)(Figure 25)
4.1.5 iNOS Activity In Biopsies From Histologically Normal Colonic Mucosa in 
Patients with Colitis
To further examine the effect of IL-4, IL-10 and IL-13 on cytokine stimulated NO 
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Figure 25. IL-8 production by colonic biopsies taken from histologically normal areas in patients 
(n=8) without colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of IL- 
8 produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three cytokines 
IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in combination (3C). Paired 
biopsies incubated with the three cytokines were also incubated with IL-4, IL-10 or IL-13 at a 
concentration of 30ng/ml for two hours prior to addition of the cytokines. IL-8 levels were 
determined in supernatants, using an ELISA specific to IL-8. To correct for differing sizes of 
biopsies, the protein content of the biopsies was estimated using a protein assay. IL-8 levels are 
expressed as ng/ml in the supernatant per lOOpgrams of protein. Each bar is the mean ± SEM of 
eight experiments. A significant effect was found using this dose of both LL-4 and IL-10 compared to 
samples stimulated with the 3C (p<0.05). There was no significant difference between IL-13 and the 
control biopsies studied. There was no significant difference between IL-4 and IL-10.
+ p<0.05 vs control
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colonic biopsies from non-inflamed areas of the colon in patients with colitis. 
(n=4) (M:F 2:2) These were patients undergoing colonoscopy for assessment of 
colitis in which there were areas that were macroscopically normal. Any patients 
who had inflammation reported in these biopsies were not included in these 
experiments.
Mucosal biopsy specimens of each patient were placed in five wells of a six well 
plate containing culture media with the appropriate stimuli per well. Three of the 
five wells were pre-treated for two hours with 30ng/ml of IL-4, IL-10 or IL-13. 
The three pro-inflammatory cytokines were then added as in the concentrations 
known to induce iNOS in HT-29 cells. After treatment, total protein was 
estimated per well and the individual nitrite content of each well was measured 
and expressed as pmoles/lOOpg Protein. (Table 11)
At 40 hours baseline nitrite production per lOOpg of protein in non-inflamed 
biopsies from patients with colitis was 405 ± 248 pmoles/lOOjig protein (control ± 
SEM). After stimulation with 3 cytokines this rose to 2139 ± 908 p<0.05. 
Pre-treatment with IL-4 at 30ng/ml significantly decreased nitrite production to 
422 ± 207 pmoles/lOOpg protein p<0.05. Pre-treatment with IL-10 at 30ng/ml 
decreased nitrite production to 227 ±138 pmoles/lOOpg (p<0.05). Pre-treatment 
with IL-13 at 30ng/ml had no significant decrease in nitrite production which fell 
to 1870 ± 1084 pmoles/100 pg. (Figure 26)
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Figure 26. Nitrite production by colonic biopsies taken from histologically normal areas in patients 
(n=4) with colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of nitrite 
produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three cytokines 
IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in combination (3C). Paired 
biopsies incubated with the three cytokines were also incubated with IL-4, IL-10 or IL-13 at a 
concentration of 30ng/ml for two hours prior to addition of the cytokines. Nitrite levels were 
determined in supernatants, using a fluorescent substrate with a 10 nM level of detection. To correct 
for differing sizes of biopsies, the protein content of the biopsies was estimated using a protein assay. 
Nitrite levels are expressed as pmoles in the supernatant per lOOpgrams of protein. Each bar is the 
mean ± SEM of 4 different patients. A significant increase in nitrite production was found when 
treating the biopsies with the three cytokines compared to controls (p<0.05). A significant inhibition 

















1 110 506 162 57 73
2 23 1129 135 29 1429
3 105 311 36 47 8
4 571 2327 511 320 2231
Table 11. Nitrite production by cultures of macroscopically normal human colonic mucosa from 
patients with colitis. Effect of pre-incubation with 30ng/ml o f either IL-4, IL-10 or IL-13 2 hours 
prior to stimulation with a 3 Cytokine mixture. All values expressed as pmoles/lOOpg protein
4.1.6 IL-8 Activity In Biopsies From Histologically Normal Colonic Mucosa in 
Patients with Colitis
At 40 hours baseline IL-8 production per lOOpg of protein in non-inflamed 
biopsies from patients with colitis was 9.1 ± 1.3 ng/100 pg protein (control ± 






3C +IL-4 3C +IL-10 3C+IL-13
1 6 14 9 7 11
2 9 19 12 10 51
3 9 15 4 1 7
4 12 29 17 17 21
Table 12. IL-8 production by cultures of macroscopically normal human colonic mucosa from 
patients with colitis. Effect o f pre-incubation with 30ng/ml o f either IL-4, IL-10 or IL-13 two 
hours prior to stimulation with a 3 Cytokine mixture. All values expressed as ng/lOOpg protein.
Pre-treatment with IL-4 at 30ng/ml significantly decreased IL-8 production that 
fell to 10.9 ± 2.6 ng/100 pg protein p<0.01. Pre-treatment with IL-10 at 30ng/ml
decreased IL-8 production to 8.0 ± 3.2ng/100 pg protein (p<0.05). Pre-treatment 
with IL-13 at 30ng/ml had no significant effect on IL-8 production that rose to
23.1 ± 9.9 ng/ lOOpg protein. (Table 12)(Figure 27)
117
35
30 + p<0.05 vs Control
* p<0.05 vs 3C
Control Cytokine X + IL -4  3C+IL-10 X + IL -13
Stimulated (3C)
Figure 27. IL-8 production by colonic biopsies taken from histologically normal areas in patients 
(n=4) with colitis. The biopsies were incubated at 37° C for 40 hours. Control is the amount of IL-8 
produced by the biopsies in 40 hours. Paired biopsies were also incubated with the three cytokines 
IL -la  (lOng/ml), TNF-a (lOOng/ml), and IFN-y (300U/ml) added in combination (3C). Paired 
biopsies incubated with the three cytokines were also incubated with IL-4, IL-10 or IL-13 at a 
concentration of 30ng/ml for two hours prior to addition of the cytokines. IL-8 levels were 
determined in supernatants, using an ELISA specific to IL-8. To correct for differing sizes of 
biopsies, the protein content of the biopsies was estimated using a protein assay. IL-8 levels are 
expressed as ng/ml in the supernatant per lOOpgrams of protein. Each bar is the mean ± SEM of four 
experiments. A significant effect was found using this dose of both IL-4 and IL-10 compared to 
samples stimulated with the 3C (p<0.05). There was no significant difference between IL-13 and the 
cytokine stimulated biopsies studied. There was no significant difference between IL-4 and IL-10.
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4.2 Discussion And Technical Points
It has previously been shown that the colonic epithelial cells HT-29 are able to 
produce IL-8 and NO in large quantities when stimulated with the combination of 
IL-1, TNF-a and IFN-y. Dr Kolios had previously shown that this production is 
easily suppressed in a dose dependant fashion using either IL-4 or IL-13 but is 
resistant to inhibition with IL-10 (Kolios et al., 1998). As the evidence to date 
suggests that both IL-8 and NO are important in the pathophysiology of 
inflammatory bowel disease and as we know that IL-10 has been used with some 
success to treat IBD, there were several possibilities as to why there was a 
difference. Firstly, was NO or IL-8 production by colonic epithelial cells 
unaffected by IL-10? Secondly, was the method of stimulating HT-29 cells with 
IL-1 a, IFN-y and TNF-a to produce NO and IL-8, effectively resistant to 
suppression with IL-10? Thirdly, was there another cell type that acted directly 
upon the colonic epithelial cell that was sensitive to IL-10? Lastly, was the HT-29 
cell so different to the normal colonic epithelial cell that it was immune to the 
effect of IL-10?
An experiment was therefore designed to look at inflamed bowel from patients 
with colitis and examine the effect of incubating them with the three cytokines 
under investigation. As can be seen from the results, IL-10 does indeed have a 
marked effect on both IL-8 and NO production as measured by nitrite production. 
As we know that NO production in the inflamed colon is almost exclusively from 
colonic epithelial cells this would suggest that IL-10 does indeed act upon colonic 
epithelial cells or another cell type that directly controls what the epithelial cells 
do. This would suggest that IL-10 when used in the management of IBD, reduces 
inflammation at least in part, by inhibiting IL-8 and NO production. Interestingly
neither IL-4 nor IL-13 at the doses examined showed any effect on NO production 
in this model. IL-4 did have an effect on IL-8 production but there was no effect 
observed with IL-13. As it is known that both of these cytokines have a marked 
effect in the epithelial cell line model it suggested that either the conditions used 
to induce NO production i.e. the combination of IFN-y, IL-1 and TNF-a in the 
epithelial cells made them sensitive to IL-4 and IL-13 and resistant to IL-10. The 
other possibility is that IL-4 and IL-13 were unable to influence sufficiently any 
other cells acting directly on the epithelial cells. Again in this study compared 
with other studies, the colonic biopsies are taken from patients who are newly 
diagnosed colitic patients and are therefore on no treatment prior to the 
experiment. Other studies looking at immunohistochemistry and other changes in 
NO biochemistry have used patients who are already well established on 
treatment often including steroids or commonly on resection specimens from 
patients who are steroid resistant, thus almost including patients who may have 
different expression of cytokines and sensitivity of immune cells to cytokines.
This effect of the IL-10 and IL-4 was also confirmed by the data from the PCR 
results looking at iNOS and IL-8 mRNA. This shows that iNOS is produced in 
colitis and that the levels of the mRNA are reduced when the inflamed biopsies 
were incubated with either IL-10 or IL-4. Although the method used is only semi- 
quantitative the evidence combined with the nitrite and IL-8 data from the 
incubated biopsies from inflamed colonic biopsies would strongly suggest that 
this is a real reduction in iNOS and IL-8 production by down regulation of 
mRNA. It also confirms that IL-13 seems to have no effect on levels of mRNA. 
Again as in chapter 3, ideally northern blot techniques would have been used, and 
again this was tried on several occasions. Unfortunately, even after 20 hours of
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incubation too much degradation of the mRNA had occurred and this did not 
allow me to proceed with this method of examining how much mRNA was 
present. Results from Western blot analysis would have also been presented to 
confirm a lowering of the product of the iNOS gene. Unfortunately within the 
time restraints allowed to do the work in, I was unable to do this.
To examine this difference between the biopsies and the HT-29 cells further the 
stimulated biopsy models were set up. This allowed us to examine the effect of 
stimulation with the cytokine mixture on the biopsies and to examine whether this 
created conditions where IL-10 was unable to act. This showed that normal 
colonic mucosa could produce large quantities of both IL-8 and NO when exposed 
to IL-1, TNFa and IFN-y. In both colitic and non-colitic patients, nitrite levels are 
easily suppressed by both IL-4 or IL-10 suggesting that the cytokine stimulated 
mucosa behaves as the inflamed mucosa does when examining NO production. 
The variable effect of IL-13 is harder to explain especially as it is closely related 
to IL-4 and is thought to use the same cellular receptor. In histologically normal 
colonic mucosa from patients without colitis, IL-13 significantly inhibits nitrite 
production, but appears to have no effect on nitrite production from cytokine 
stimulated normal colonic mucosa from subjects with colitis. This lack of effect of 
IL-13 mirrors that seen in the inflamed colitic mucosa biopsy model. Why there 
should be this difference is unclear, but does suggest that even in histologically 
normal mucosa there are differences that are present in colitic individuals. 
Whether the structural cells of the colon e.g. epithelial cells, lamina propria cells 
are abnormal in colitic patients and behave like cells from inflamed mucosa when 
stimulated in the appropriate manner or whether the more mobile population of
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circulating white cells can, when appropriately stimulated, induce a colitis thus 
explaining the similarities between non-inflamed and inflamed colitic bowel.
When looking at IL-8 production we have shown that normal colonic mucosa both 
from colitic and non-colitic patients can be stimulated to produce IL-8 in large 
quantities when incubated with the combination of IL-1, TNF-a and IFN-y. Pre­
treatment with either IL-4 or IL-10 can effectively inhibit this production. 
However, IL-13 again seems to have no effect on either IL-8 production in both 
the colitic and non-colitic model.
The general lack of effect of IL-13 seems consistent throughout all the colonic 
biopsy data even though it was being used at doses that had been shown to be very 
effective in the stimulated HT-29 model. The other striking difference was that 
IL-10 seemed very effective in the biopsy data even though there was no effect at 
all in the stimulated HT-29 cell model.
To examine further why IL-10 has a marked effect on NO production in all the 
biopsy models but has no effect on HT-29 cells it was proposed that in feet it may 
be acting upon white cells which in turn have an effect on colonic epithelial cells. 
It is apparent that as the epithelial cells in the colon are thought to be the exclusive 
source of NO production that IL-10 must be having an effect either directly on 
epithelial cells or on other cells that have an effect on the colonic epithelial cells.
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Chapter 5: RESULTS 
The Interaction of Mixed Mononuclear Cells and Colonic
Epithelial Cells. Controlling Factors Affecting Inducible Nitric
Oxide Expression
5.1 Effect Of Different Stimuli On A Co-Culture Of HT-29 Cells And Mixed 
Mononuclear Cells.
With the difference between the ability of steroids and IL-10 to inhibit nitric oxide 
production in cytokine stimulated HT-29 cells and the stimulated normal mucosa, 
a series of experiments was set up to see if these responses could be reproduced 
with HT-29 cells being stimulated by cytokine stimulated mixed mononuclear 
cells.
Initial experiments were performed to see whether HT-29 cells co-cultured with 
mixed mononuclear cells produced any significant nitrite production. HT-29 cells 
and mixed mononuclear cells were cultured on their own and also co-cultured 
together. A variety of different stimuli were added to see whether conditions 
could be created where stimuli could be added to the co-culture of the two cell 
populations and excess nitrite produced over and above baseline nitrite 
production. The same stimuli when added to the isolated populations of cells 
should result in no nitrite production over and above basal production. A variety 
of possible stimuli were examined such as the stimuli already known to induce 
NO production in the HT-29 cells e.g. IL-1 a, TNF-a and IFN-y. Each of these 
was tried on their own and in combination with each other and another possible 
stimuli e.g. lipopolysaccharide.
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HT-29 Unstimulated 471 ±25
HT-29+IL-1+TNF+IFN 1068 ±158
MMCs alone 446 ±47
HT-29+ MMCs 481 ±13
HT-29+ MMCs+ IFN 457 ±69
HT-29+ MMCs+ IL-1 421 ±49
HT-29+MMCs+TNF 511± 113
HT-29+ MMCs+ LPS 496 ± 76
HT-29+ MMCs+ LPS+TNF 386 ±46
HT-29+ MMCs+LPS+IL-1 354 ±112
HT-29+ MMCs+LPS +IFN 1425 ± 120
HT-29+ LPS+IFN 676 ± 68
MMCs+ LPS+IFN 568 ±121
Table 13. Nitrite production by cultures of HT-29 cells and MMCs. Effect o f incubation with a 
variety o f pro-inflammatory stimuli. All values expressed as pmoles/106 cells
Basal nitrite production by unstimulated growth arrested HT-29 cells at 48 hours 
was 471 ± 25 pmoles/106 cells (mean ± SEM). Nitrite production from isolated 
mixed mononuclear cells was not significantly different at 446 ± 47 pmoles/106 
cells. When HT-29 cells were co-cultured with MMCs in control media there was 
no significant increase in nitrite production over unstimulated HT-29 cells with 
production at 481 ±13 pmoles/106 cells. HT-29 cells stimulated with IFN-y and 
LPS did not change nitrite production significantly compared with unstimulated 
HT-29 cells with production being 676 ±68 pmoles/106 cells. Nitrite production in 
MMCs stimulated with IFN-y and LPS also did not change significantly with 
production at 568 ± 120 pmoles/106 cells. When co-cultured together and
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stimulated with LPS and IFN-y rose significantly to 1425 ±120 pmoles/106 cells 
(p<0.05). (Table 13) (Figure 28). MMCs stimulated with LPS and IFN-y for 6 
hours were then centrifuged at high speed and then the supernatant removed from 
above the cellular pellet. This conditioned media was then transferred to confluent 
growth arrested confluent HT-29 cells and incubated for a further 42 hours. This 
conditioned media was able to cause a significant rise in nitrite production by 
HT-29 cells at 48 hours to 1380 ± 170 pmoles/106 cells (p<0.05). (Figure 29)
5.2 Effect Of Prednisolone and Budesonide On A Co-Culture Of HT-29 Cells 
And Stimulated Mixed Mononuclear Cells.
As stated above it was shown that the combination of LPS and IFN-y could not 
induce NO production as measured by an increase in nitrite above basal 
production in either the HT-29 cells or the MMCs when cultured alone. When the 
two types of cell were co-cultured together in the presence of LPS and IFN-y a 
significant increase in nitrite could be measured. A dose response curve was able 
to be demonstrated when the co-culture of HT-29 cells and MMCs was pre-treated 
with either prednisolone or budesonide. A significant suppression occurred at 
doses of 30nM for prednisolone and all doses of budesonide tested. In a treated 
co-culture the nitrite production rose from 473 ±107 pmoles/106 cells to 1203 ± 
138 pmoles/106 cells. The nitrite production at a dose of 30nM fell to 728 ±99 
pmoles/106 cells for prednisolone (p<0.05) and 550 ± 71  pmoles/106 cells for 
budesonide treated cells (p<0.05) (Figure 30) (Table 14).
Media transferred from the stimulated MMCs was able to stimulate nitrite 
production in the HT-29 cells from the basal level of 478 ±107 pmoles/106 cells 
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Figure 28. Nitrite production by HT-29 cells and mixed mononuclear cells after 48 hours 
cultured alone or co-cultured together and stimulated with a variety of different stimuli. Adherent 
starved HT-29 cells were confluent at the bottom of a standard six well plate at an approximate 
density of 3.5 x 106 cells per well. The MMCs were at a concentration of 500,000/ml. The HT-29 
and MMCs when co-cultured with LPS and IFN-y produced a significant increase in nitrite 
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Figure 29. Nitrite production by the colonic epithelial cell line HT-29 and mixed mononuclear 
cells (MMCs) from normal volunteers (n=6). HT-29 cells and MMCs were incubated at 37°C 
either separately or together for 30 hours and were stimulated with lipopolysaccharide and 
IFN-y (300U/ml) added in combination. Nitrite levels were determined in supernatants, using a 
fluorescent substrate with a 10 nM level of detection. Nitrite levels are expressed as pmoles in 
the supernatant per lOOpgrams of protein. Each bar is the mean ± SEM of 6 different 
experiments. The basal production of nitrite by HT-29 cells is shown in the first column. The 
second column shows nitrite production when MMCs and HT-29 cells when co-cultured 
together. A significant increase in nitrite production was found when treating the co-culture 
with the LPS and IFN-y compared to basal production (p<0.05). A significant increase in nitrite 
production was also found when incubating the HT-29 with media from the LPS and IFN-y 
stimulated MMCs compared to basal production (p<0.05). No significant increase in nitrite was 
noted when HT-29 cells were treated with LPS and IFN-y.
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Figure 30. Concentration of nitrite produced by a co-culture of HT-29 cells and MMCs. 
Adherent starved HT-29 cells were confluent at the bottom of a standard six well plate at an 
approximate density of 3.5 x 106 cells per well. The MMCs were at a concentration of 
500,000/ml. The co-cultures were pre-treated with prednisolone or budesonide at one of three 
different doses for two hours prior to stimulation with LPS and IFN-y. Supernatant was removed 
at 48 hours and analysed for nitrite concentration. All three doses of budesonide produced a 
significant reduction in nitrite generation (p<0.05). Prednisolone at a dose of 30nM produced a 
significant reduction in nitrite generation (p<0.05)
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treated with either prednisolone or budesonide at a dose of 30nM and then after 
one hour media from stimulated MMCs was transferred. No significant change 
was found with either prednisolone or budesonide in nitrite production. With 
prednisolone this was found to be 1595 ± 126 pmoles/106 cells and with 
budesonide 1486 ±168 pmoles/106 cells. (Figure 31) However, if the MMCs were 
pre-treated with either prednisolone or budesonide prior at a dose of 30nM prior 
to stimulation with IFN-y and LPS and then the conditioned media was transferred 
then significant falls were found in nitrite production by the HT-29 cells. With 
prednisolone, nitrite production fell to 624 ±141 pmoles/106 cells (p<0.05). With 
budesonide it fell to 741 ±91 pmoles/106 cells (p<0.05). (Figure 32).
Prednisolone Budesonide
473 473
Stimulated Co-culture 1203 1203
Stimulated Co-culture + 3 nM 1057 610
Stimulated Co-culture +10nM 937 663
Stimulated Co-culture +30nM 729 550
Table 14. Nitrite production by cultures o f HT-29 cells and MMCs. Effect of incubation with 3 ,10  
or 30nM o f either prednisolone or budesonide. All values expressed as pmoles/106 cells
5.3 Effect Of IL-4, IL-10 and IL-13 On A Co-Culture Of HT-29 Cells And 
Stimulated Mixed Mononuclear Cells.
At 48 hours basal nitrite production by unstimulated HT-29 cells was 478 ±107 
pmoles/106 cells (control ± SEM). When the co-culture was stimulated with IFN-y 
and LPS nitrite production rose significantly to 1203 ±138 pmoles/106 cells 
(p<0.05). The co-culture was pre-treated with IL-4, IL-10 or IL-13 at doses of 
3nM, lOnM or 30nM. The cells were then stimulated with LPS and IFN-y at the 
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Figure 31. Nitrite production by a culture of serum depleted HT-29 cells treated with 
conditioned media from MMCs stimulated with LPS and IFN-y. The effect of pre-treatment with 
steroids on the HT-29 cells prior to the addition of the conditioned media was assessed. A 
significant rise in nitrite was found with the addition of the conditioned media. Pre-treatment with 
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Figure 32. Nitrite production by serum depleted HT-29 cells treated with conditioned media 
from LPS and IFN-y stimulated MMCs. The MMCs were pre-treated with prednisolone or 
budesonide at a concentration of 30nM for 2 hours prior to stimulation with the LPS and IFN-y. 
There was a significant decrease in nitrite production by the HT-29 cells when conditioned media 
was used from MMCs that had been pre-treated with either prednisolone or budesonide (p<0.05).
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production was demonstrated for pre-treatment with IL-4, IL-10 and IL-13 with a 
significant suppression for all 3 cytokines at doses of 30nM. In addition pre- 
treatment with all doses of IL-10 showed a significant fall in nitrite production 
and IL-4 also showed a significant suppression of nitrite production at lOnM. 
(Figure 33) (Table 15)
IL-4 IL-10 IL-13
Co-culture of MMCs and HT-29 cells 478 ±107 478 ±107 478 ±107
Stimulated Co-culture 1203 ± 103 1203 ± 103 1203 ± 103
Stimulated Co-culture + 3 ng/ml 818 ±103 583 ±31 1126 ±58
Stimulated Co-culture +10ng/ml 505 ± 35 468 ±38 950 ±102
Stimulated Co-culture +30ng/ml 408 ±41 344 ±27 666 ± 61
Table 15. Nitrite production by cultures o f HT-29 cells and MMCs. Effect o f incubation with 
doses o f 3, 10 or 30ng/ml of IL-4, IL-10 or IL-13. All values expressed as pmoles/106 cells (mean 
± SEM)
Media transferred from the stimulated MMCs was able to stimulate nitrite 
production in the HT-29 cells from the basal level of 478 ±107 pmoles/106 cells 
to 1680 ±170 pmoles/106 cells.
IL-4 IL-10 IL-13
Co-culture Of MMCs and HT-29 cells 478 ±107 478 ±107 478 ±107
HT-29 cells + conditioned media from 
MMCs
1680 ±170 1680 ± 
170
1680 ±170
Pre-treated HT-29 cells + conditioned 
media from MMCs
1775 ±156 1763 ±94 1319 ±157
HT-29 cells + conditioned media from Pre­
treated MMCs
818 ±60 673 ± 76 843 ±29
Table 16. Nitrite production by cultures o f HT-29 cells and MMCs. Effect o f pre-treatment of 
either HT-29 cells or MMCs with doses o f 30ng/ml of IL-4, IL-10 or IL-13. All values expressed 
as pmoles/106 cells (mean ± SEM)
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* p<0.05 vs stimulated co-culture
Control
Stimulated co-culture 
Stimulated co-culture + IL-4 
Stimulated co-culture +IL-10 
Stimulated co-culture +IL-13
C ontrol Stimulated 3ng/ml lOng/ml 30ng/ml 3ng/ml lOng/ml 30ng/ml 3ng/ml lOng/ml 30ng/ml 
Co-culture
Figure 33. Nitrite concentration in stimulated co-cultures of HT-29 cells and MMCs. The co­
cultures were stimulated with LPS and IFN-y. Prior to stimulation the co-cultures were pre­
treated with increasing concentrations of IL-4, IL-10 or IL-13. Three different doses were used of 
these cytokines: 3,10 and 30 ng/ml. A significant reduction in nitrite was seen at all doses of 
IL-10, IL-4 and IL-13 had a significant reduction of nitrite at a dose of 30ng/ml. In addition a 
dose of lOng/ml of IL-4 was found to reduce nitrite production significantly.
A culture of growth arrested HT-29 cells was pre-treated with either IL-4 IL-10 or 
IL-13 at a dose of 30ng/ml and then after one hour media from stimulated MMCs 
was transferred. No significant change in nitrite production was found with IL-4 
(1775 ± 156 pmoles/106 cells), IL-10 (1763 ± 94 pmoles/106 cells) or IL-13 (1319 
±157 pmoles/106 cells) (Figure 34). However, if the MMCs were pre-treated with 
IL-4, IL-10 or IL-13 at a dose of 30ng/ml prior to stimulation with IFN-y and LPS 
and the transfer of the conditioned media then significant falls were found in 
nitrite production by the HT-29 cells. With IL-4, nitrite production fell to 818 ± 
60 pmoles/106 cells (p<0.05). With IL-10 it fell to 673 ± 76 pmoles/106 cells 
(p<0.05) and with IL-13 it fell to 843 ±29 pmoles/106 cells (p<0.05). (Table 16) 
(Figure 35)
5.4 Effect Of An Inhibitory Substance On A Co-Culture Of HT-29 Cells And 
Stimulated Mixed Mononuclear Cells.
The effect of the inhibitory substance IL-1 receptor antagonist (IL-lra) was 
examined on the co-culture of HT-29 cells and MMCs. Firstly, a series of 
experiments were performed to find the appropriate dose of the IL-lra. A growth 
arrested monolayer of HT-29 cells were pre-treated with a variety of doses of 
either the IL-lra and were then stimulated with IL-1 a, TNFa and IFN-y at the 
doses previously described. When the pre-treated HT-29 cells showed a 
significant fall in nitrite production and led to similar levels to that produced with 
only two pro-inflammatory cytokines being used, this dose was then used in 
future experiments. This dose of either IL-lra was then used either to pre-treat the 
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Figure 34. Nitrite production by a culture of serum depleted HT-29 cells treated with conditioned 
media from MMCs stimulated with LPS and IFN-y. The effect of pre-treatment with T cell 
derived cytokines (IL-4, IL-10 and IL-13) on the HT-29 cells prior to the addition of the 
conditioned media was assessed. A significant rise in nitrite was found with the addition of the 
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Figure 35 Nitrite production by a culture of serum depleted HT-29 cells treated with conditioned 
media from MMCs stimulated with LPS and IFN-y. The effect of pre-treatment with T cell 
derived cytokines (IL-4, IL-10 and IL-13) on the MMCs cells prior to the addition of the LPS and 
IFN-y was assessed. A significant rise in nitrite was found with the addition of the conditioned 
media. A significant effect of all three of the cytokines on the MMCs was found (p<0.05).
cells prior to the addition of the conditioned media. When the HT-29 cells were 
pre-treated with IL-lra then nitrite production fell to 991 ± 125 pmoles/106 cells 
(p<0.05). If the MMCs were pre-treated with II-Ira then there was no significant 
change in nitrite production with levels of nitrite of 1782 ±151 pmoles/106 cells. 
(Figure 36) (p<0.05).
IL-lra
Co-culture Of MMCs and HT-29 cells 478 ±107
HT-29 cells + conditioned media from 
MMCs
1680 ±170
Pre-treated HT-29 cells ± conditioned media 
from MMCs
991 ± 125
HT-29 cells ± conditioned media from Pre­
treated MMCs
1782 ± 151
Table 16. Nitrite production by cultures o f HT-29 cells and MMCs. Effect o f pre-treatment of 
either HT-29 cells or MMCs with doses of 30ng/ml o f IL-lra. All values expressed as pmoles/106 
cells (mean ± SEM)
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Figure 36 Nitrite production by a culture of serum depleted HT-29 cells treated with conditioned 
media (CM) from MMCs stimulated with LPS and IFN-y (n=4). The effect of pre-treatment with 
IL-lra on the cells prior to addition of CM was assessed. The effect of pre-treating the MMCs 
with IL-lra prior to stimulation with LPS and IFN-y was also assessed. When the HT-29 cells 
were pre-treated with the IL-lra prior to the addition of the CM a significant fall in nitrite was 
found (p<0.05). No change in nitrite production was found when MMCs were pre-treated prior to 
stimulation with the LPS and IFN-y.
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5.5 Discussion and Technical Points
With the data presented in the early chapters it is apparent that the HT-29 cells 
behave differently from both inflamed and stimulated biopsies. This difference is 
most pronounced when looking at the effect of IL-10 on stimulated HT-29 cells. 
The data first presented by Dr Kolios shows clearly that IL-10 is unable to inhibit 
NO production by iNOS in a culture of HT-29 cells. Because in inflamed tissue 
the epithelial cells are not in isolation and are likely to be influenced by cytokines 
and other substances produced in the inflammatory reaction, it was decided to see 
if a co-culture could more easily reproduce the results from the biopsies. Because 
intra-epithelial lymphocytes (IEL) are the likeliest cells to be involved, 
mononuclear cells were chosen for the co-culture. Although peripheral mixed 
mononuclear cells are likely to be different in some respects from IELs, they are 
the easiest population of similar cells to obtain in large enough numbers to 
perform multiple co-culture experiments.
The author has shown that HT-29 cells stimulated with LPS and IFN-y do not 
produce nitrite and that isolated MMCs stimulated with LPS and IFN-y do not 
produce excess NO as measured by nitrite. Also when co-cultured together in the 
absence of any stimulation again no increase in NO production is found. However 
when HT-29 cells are co-cultured with stimulated MMCs they do produce large 
quantities of NO. Pre-treating the MMCs with low doses of prednisolone or 
budesonide easily inhibits this. These doses of steroids are similar to that used in 
the biopsy models and do not have to be used at the very high doses that have to 
be used to obtain an effect on the stimulated HT-29 cells.
The data also shows that the HT-29 cells and the MMCs do not need to be in 
contact and NO production by HT-29 cells can be induced by transferring media
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from IFN-y and LPS stimulated MMCs. This would suggest that although the 
epithelial cells are the site of production of NO by iNOS, this production is 
always dependant on stimulation of the epithelial cells with external cellular 
factors. The fact that media transferred from stimulated MMCs can induce this 
production shows that these factors are soluble.
This data strongly suggests that the mononuclear cells are the main site of action 
of the steroids prednisolone and budesonide when considering the reduction in 
NO production noted in this biopsy study and is the likely cellular site of action in 
previous studies noting a fall in NO production in treated colitis.
This NO production by the HT-29 cells, as measured by nitrite, is easily inhibited 
by pre-treating the MMCs with small doses of either IL-4 or IL-10. IL-13 did 
have an effect but this was much less marked and only at a dose of 30ng/ml. If 
HT-29 cells were pre-treated with 30ng/ml of IL-4, IL-10 or IL-13 and then 
transferred conditioned media from the MMCs then no reduction in nitrite was 
seen. However this ability of the conditioned media to induce nitrite was easily 
blocked by pre-treating the MMCs with any of the anti-inflammatory cytokines. 
This data suggests that the production of soluble factor or factors produced by the 
mononuclear cells can be inhibited by both IL-4, IL-10 and to a lesser extent 
IL-13. This may explain the effect seen in NO production noted in this biopsy 
study compared with just the HT-29 cell model when examining IL-10. 
Pre-treatment of the HT-29 cells with IL-lra inhibits the effect of the conditioned 
media. The effect of the IL-lra was not seen when directly treating the MMCs 
with the IL-lra. This would suggest that IL-1 is one of the soluble factors secreted 
by the stimulated MMCs that are necessary to induce NO production in colonic 
epithelial cells.
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No data concerning the MMCs and HT-29 model with respect to the production of 
IL-8 has been presented as when the MMCs are stimulated with IFN-y and LPS, 
large quantities of IL-8 are released, thus rendering it impossible to examine the 
effect on the HT-29 cells.
It has been shown in previous studies that the when HT-29 cells are incubated in 
the presence of IFN-y, the cells can become antigen presenting cells. This in 
theory could suggest that the MMCs are interacting directly with the HT-29 cells 
once they have in turn become antigen-presenting cells and produce cytokine 
production and cell death. This would appear unlikely in our study partly because 
of the small amount of time the two populations of cells are together, and also 
because of the experiments where the MMCs and the HT-29 cells were cultured 
apart but that conditioned media from the MMCs was transferred from to the 
HT-29 cells. This last experiment clearly shows that the two populations of cells 
do not actually need to be in physical contact but that media removed from 
stimulated MMCs can induce NO production in the HT-29 cells as measured by 
nitrite.
This data suggests that although the colonic epithelial cell is essential for the 
production of NO in any colonic inflammation, it is necessary for other cell types 




The role of the epithelial cell in the aetiology and pathogenesis of inflammatory 
bowel disease remains unclear. There is now a large amount of evidence to 
suggest that the epithelial cell not only acts as a barrier and as part of the 
absorptive surface, but also has an important role in the initiation of the 
inflammatory response. The role of the epithelial cell in the inflammatory 
response is suggested by the ability of the epithelial cells to present antigens via 
class II MHC expression (Lowes et a l, 1992), express adhesion molecules such as 
ICAM-1 (Dippold et al., 1993) and produce soluble mediators such as cytokines 
(Jung et al., 1995).
It is also known that in inflammatory states of the colon e.g. ulcerative colitis, 
Crohn’s disease and infectious colitis in humans that large quantities of NO are 
produced (Lundberg et al., 1994;Rachmilewitz et al., 1995a). The colonic 
epithelial cell has been shown to be the exclusive site of production of NO by 
iNOS in the inflamed colon. Due to generation of toxic breakdown products such 
as peroxynitrite, excess nitric oxide has been implicated in the inflammatory 
response. The effect of inhibition of nitric oxide inhibition has been described in 
an animal model of colitis. This has shown that the severity of the colitis is 
ameliorated (Neilly et a l, 1996). The relevance of this to the colitis seen in 
humans in the inflammatory bowel disease is still open to discussion. Indeed, 
evidence from iNOS “knockout” mice has suggested that nitric oxide as produced 
by iNOS has a role in reducing the inflammation found in inflammatory bowel
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disease (McCafferty et a l, 1997). Animal models of colitis are usually rat models, 
where the colon is exposed to a toxic substance e.g. dextran sulphate or TNBS. 
Whether this is strictly relevant to the inflammation seen in UC and Crohn’s 
disease is still debated, where the inflammation seen in IBD may be an unusual 
response to an environmental substance or pathogen but could instead be a 
primary immunological defect.
IL-8 in contrast to nitric oxide produced by iNOS is produced by many cell types 
for example immune cells, fibroblasts and endothelial cells as well as the 
epithelial cell (Baggiolini et a l , 1994). Thus changes found when looking at the 
effect of a particular treatment on a colonic biopsy that showed an effect on iNOS 
would suggest that the epithelial cell is the primary site of action. If an effect was 
noted on IL-8 but not on iNOS expression then this would suggest that the 
epithelial cell is not the primary site of action.
There are many published experiments examining the response of colonic 
epithelial cell lines to various stimuli. Isolated primary human colonic epithelial 
cells have many problems being kept alive past 48 hours, thus cell lines are used, 
as they are immortal. This avoids the possible problem that any response seen in 
primary epithelial cells could be argued to be the response of a “dying” cell. 
However, work using cell lines can also be argued to be the response of abnormal 
cells due to the fact that they have large changes to their genetic structure. 
However, this may be the only way to study cells such as the colonic epithelial 
cell in isolation. Previous cell line work studying colinic epithelial cells such as 
the HT-29 cells has demonstrated that they are able to produce large quantities of 
nitric oxide and IL-8 when appropriately stimulated (Kolios et a l, 1995; Salzman 
et a l , 1996).
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The experiments described here were designed to examine the relationship 
between the responses already described in HT-29 cells and the response of the 
colonic epithelial cell in the colon. Specifically I was examining the controlling 
mechanisms of NO production by iNOS and IL-8 production. One of the 
mainstays of treatment of both ulcerative colitis and Crohn’s disease are steroids. 
It would therefore be expected that steroids would have an effect on NO 
production by iNOS, an enzyme known to be upregulated in inflammation. 
Similarly, because it is known that IL-10 deficient mice will naturally develop a 
colitis unless kept in a sterile environment, IL-10 is thought to be a key “anti­
inflammatory” cytokine possibly deficient or defective in those who develop 
colitis. There has been some limited success with therapeutic trials of IL-10 in the 
management of inflammatory bowel disease (Schreiber et al., 1995b).
In the experiments described here, there are some marked differences in the 
experiments using growth arrested monolayers of the immortal HT-29 cells, from 
the more physiological models described. The stimulated HT-29 cells are 
relatively immune to suppression of iNOS by steroids, although iNOS expression 
in other cell lines and cell types, both animal and human, do appear more sensitive 
to suppression by steroids e.g. the lungs (Yates et al., 1995), rat mesangial cells 
(Pfeilschifter, 1991), Caco-2 cells (Cavicchi and Whittle, 1999), rat peritoneal 
neutrophils (McCall et al., 1991) and RAW 264.7 cells (Walker et al., 1997).
The results looking at the production of nitric oxide as measured by nitrite in 
colonic biopsies, which are inflamed due to colitis, are described here. Firstly 
there is marked expression of NO in the inflamed mucosa causing a large quantity 
of nitrite to be able to be measured in the culture media. This is easily measured 
and would appear to be due to the expression of inducible nitric oxide synthase,
an enzyme not normally detectable in the mucosa. Immunohistochemical studies 
have shown that there is a strong expression of iNOS in inflamed bowel from 
patients with colitis (Kolios et al., 1998;Singer et a l, 1996;Godkin et al., 1996). 
The experiments described in chapter 3 show that the enzyme transciption appears 
to be very sensitive to inhibition by steroids. This would correspond with the 
expected findings clinically. There is no discernible difference between the two 
steroids although budesonide is thought to be more potent on a molar for molar 
basis. This may be explained by the fact that both steroids are being used in 
dosages that have an effect and to demonstrate a difference we would have to 
have used even smaller doses of the steroids. It is however very obvious that the 
doses needed to get any response in the HT-29 cells are approximately 1000 times 
higher than the doses used that obtained a response in the inflamed biopsies. The 
dose used in the biopsy model would be much closer to a dose likely to be 
obtained in the tissues when a patient was treated with oral steroids.
Three possible explanations for this difference exist. Firstly that either the HT-29 
cells are immune to steroids, whilst the colonic epithelial cells found in colonic 
mucosal biopsies are sensitive to steroids. Secondly the stimuli needed to induce 
iNOS expression in HT-29 cells i.e. IL-la, IFN-y and TNF-a do not render 
colonic epithelial cells immune to the effects of the steroids. It is not known from 
this model whether the steroids are acting directly on the epithelial cells or are 
acting upon other cells stimulating the epithelial cells.
To examine this further non-inflamed biopsies from histologically normal colon 
were taken and stimulated with the same cocktail of pro-inflammatory cytokines 
e.g. IL-la, IFN-y and TNF-a. This again enabled large quantities of nitric oxide 
to be measured as the breakdown product nitrite. It was shown the enzyme iNOS
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was expressed in the stimulated biopsies, suggesting that this was contributing at 
least in part to the production of the nitric oxide, as no PCR product of iNOS was 
demonstrable in the unstimulated colonic biopsies, but was clearly present in the 
stimulated biopsies. Steroids were still found to have a marked effect on the 
production of IL-8 by the biopsies. As IL-8 is known to be expressed and 
produced by a wide variety of cell types, not only by the epithelial cell, this data 
suggests that the steroids are possibly acting upon cell types other than the 
epithelial cell. To examine this further the HT-29 cell and Mixed mononuclear 
cell model was developed.
When examining the role of IL-10 in the regulation of iNOS expression, there are 
again differences between the known work and the small amount of data that is 
available about the possible clinical action of IL-10. Again because IL-10 is 
thought to be a key cytokine in the pathogenesis of inflammatory bowel disease, it 
would be imagined that IL-10 would have an effect on iNOS expression.
From the work of Dr Kolios it is known that iNOS expression by HT-29 cells was 
unable to be inhibited by IL-10 (Kolios et a l , 1998). This is in contrast to the 
effect of IL-10 on iNOS expression in other cell systems (Cunha et ah, 1992). In 
human macrophages IL-10 reduced NO synthesis by down-regulating iNOS at the 
transcriptional level (Dugas et a l , 1998). Similarly in human keratinocytes IL-10 
inhibits IgE mediated iNOS induction and thus reduces NO production (Becherel 
et a l , 1995). However, iNOS expression in murine macrophages treated with 
TNFa and IFN-y and avian osteoclast-like cells is actually increased when treated 
with IL-10 (Sunyer et a l, 1996;Zidek and Frankova, 1999). However as in HT-29 
cells, rat aortic smooth muscle cells would appear more sensitive to the inhibition
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of iNOS induction by IL-13 than IL-10 (Ruetten and Thiemermann, 1997). Again 
several possible explanations exist, firstly there could be a different regulation of 
iNOS in colonic epithelial cells compared to other cell types, or the HT-29 cells 
do not have an intact IL-10 receptor complex pathway due to the fact that they are 
adenocarcinoma cells and thus have significant changes in their genetic structure 
or lastly that the target cell of IL-10 in colonic mucosa is different. It is known 
that IL-10 does bind to the surface of HT-29 cells thus implying that the receptor 
is present on the cell surface but whether the receptor functions normally is 
unknown (Bourreille et al, 1999). Although Dr Kolios showed no discernible 
effect of IL-10 on stimulated HT-29 cells, there are marked differences found in 
both iNOS and IL-8 production when the cells are pre-treated with both IL-4 and 
IL-13 (Kolios e ta l, 1998).
The experiments I have described here have demonstrated a clear effect of IL-10 
on the colonic biopsies. It reduces production of both IL-8 and NO production due 
to iNOS in the inflamed biopsies from patients with ulcerative colitis. It is also 
able to inhibit NO production by inhibition of iNOS in cytokine stimulated 
histologically normal biopsies. A possible explanation for this includes the 
potential that IL-10 is acting on another cell type which normally acts upon the 
epithelial cell to stimulate NO production by induction of iNOS. Another possible 
explanation is that as with the lack of steroid effect on the colonic epithelial cell 
line, the combination of IL-1, TNF-a and IFN-y stimulates the production of nitric 
oxide in a way that prevents inhibition by IL-10, but would enable inhibition by 
IL-4 and IL-13.
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Thus non-inflamed biopsies from histologically normal colon were again taken 
and stimulated with the same cocktail of pro-inflammatory cytokines e.g. IL-la, 
IFN-y and TNF-a. This again enabled large quantities of nitric oxide to be 
measured in the supernatant as the breakdown product nitrite. Again the enzyme 
iNOS could be shown to be expressed in the biopsies, suggesting that this was 
contributing at least in part to the production of the nitric oxide, as no PCR 
product of iNOS was demonstrable in the unstimulated colonic biopsies, but was 
clearly present in the stimulated biopsies. These experiments also showed that this 
IL-4, IL-10 and IL-13 were able to suppress NO production by iNOS in 
stimulated biopsies. IL-4 and IL-10 were found to have a marked effect on the 
production of IL-8 by the stimulated biopsies. IL-13 had no significant effect on 
the IL-8 production in these stimulated biopsies.
A further section of the study was to look at histologically normal mucosa from 
those patients with proven colitis. In patients with colitis that there is often a sharp 
cut off between inflamed areas and non-inflamed areas despite them being 
exposed to approximately the same intraluminal conditions. The reason for this is 
unclear and could be due to a variety of different factors. A possible explanation 
is that in some way the vascular supply is different in the inflamed areas 
compared to the non-inflamed areas. Another possible explanation could be that 
the mucosa behaves differently between the two areas to the presence of the 
stimuli that initites the inflammatory response in colitis. This different response 
could be initiated by differences in the colonic epithelial cell. Thus the same 
stimulation experiments of histologically normal mucosa from patients with active 
colitis were performed as on the normal mucosa from patients whose colonic 
mucosa was normal throughout. These experiments showed that the NO
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production in histologically normal mucosa from colitic patients was low and 
approximately equal to the NO production from normal mucosa. When stimulated 
with the pro-inflammatory cytokine mix the NO production rose sharply. This 
production could be inhibited by either the prednisolone or the budesonide in a 
similar way to that from the stimulated normal mucosa from patients without 
colitis. A similar response was also seen when looking at IL-8 production by the 
biopsies. Again the IL-8 levels were low in non-stimulated biopsies and then rose 
to high levels when stimulated with the pro-inflammatory cytomix. Incubating the 
stimulated biopsies with either of the two steroids could inhibit this production of 
IL-8.
With these differences in responses to both steroids and IL-10 between the 
inflamed biopsies, the cytokine stimulated histologically normal biopsies and the 
cytokine stimulated HT-29 cells further experiments were designed to examine if 
these responses could be reproduced. The basis of this was the model of a co- 
culture of HT-29 cells and mixed mononuclear cells. The experiments were 
designed to see if a single stimulus or group of stimuli could be found that led to 
the mixed mononuclear cells being able to stimulate in turn the HT-29 cells. I 
have first shown that HT-29 cells treated with LPS and IFN-y do not produce 
nitrite above the basal level and that LPS and IFN-y stimulated MMCs do not 
produce excess NO. Also when co-cultured together in the absence of any 
stimulation again no increase in NO production is found. However when HT-29 
cells are co-cultured with LPS and IFN-y stimulated MMCs they do produce large 
quantities of NO.
Pre-treating the MMCs with low doses of prednisolone or budesonide easily 
inhibited this production of large quantities of NO. Again the doses that are
needed to be used are 1000 times less than those needed to get any inhibition in 
directly stimulated HT-29 cells. A further set of experiments were done with the 
“conditioned” media being transferred from stimulated MMCs again being able to 
show significant production of NO by the HT-29 cells. This shows that the HT-29 
cells and the MMCs do not need to be in contact and NO production by HT-29 
cells can be induced by transferring media containing soluble factors produced by 
the IFN-y and LPS stimulated MMCs. This can be easily inhibited by low doses of 
steroids, as is the production by the inflamed biopsies. This suggests that although 
the epithelial cell is the site of production of NO by iNOS, this production in the 
mucosa is likely to be dependant on stimulation of the epithelial cells with 
external cellular factors.
This data considering the reduction in NO production noted in this biopsy study 
strongly suggests that mononuclear cells are likely to be the main site of action of 
the steroids prednisolone and budesonide. This is the probable site of action when 
considering the colon as a whole especially with studies noting a fall in NO 
production in treated colitis (Lundberg et a l , 1994). This may allow the 
mechanism of this down regulation to be explored further thus allowing a more 
precise mechanism of treatment in colitis.
I also set out to examine the effect of the three “anti-inflammatory” cytokines, 
IL-4, IL-10 and IL-13 on this co-culture of stimulated MMCs and HT-29 cells. 
The production of nitric oxide is easily inhibited by pre-treating the MMCs with 
small doses of either IL-4 or IL-10 (3ng/ml). IL-13 did have an effect but this was 
much less marked and only at a dose of 30ng/ml. Again, the soluble factors in the 
conditioned media from the stimulated MMCs were shown to stimulate the HT-29 
cells to produce nitric oxide.
This co-culture model was then used to try and ascertain the principal site of 
action of the anti-inflammatory cytokines. Because we know that this production 
can be induced by the conditioned media transferred from stimulated MMCs thus 
showing that this media contained factor or factors that are soluble. If we pre­
treated the HT-29 cells with 30ng/ml of IL-4, IL-10 or IL-13 and then transferred 
conditioned media from the MMCs then no reduction in nitrite was seen. 
However this ability of the conditioned media to induce nitrite was easily blocked 
by pre-treating the MMCs with any of the anti-inflammatory cytokines. This data 
leads to two conclusions. Firstly it suggests that the mononuclear cells produce a 
soluble factor that induces colonic epithelial cells to produce nitric oxide. 
Secondly, that the production of these factors by MMCs are inhibited by both 
IL-4, IL-10 and to a lesser extent IL-13. This may explain the effect seen in NO 
production noted in this biopsy study compared with just the HT-29 cell model 
when examining IL-10. One interesting observation from these experiments with 
the transfer of conditioned media is that nitric oxide production by the HT-29 
cells is not inhibited by pre-treating with the IL-4 or IL-13 unlike in the 
experiments described by Dr Kolios where HT-29 cells were stimulated directly 
with IL-1, TNF and IFN-y. This may suggest that the HT-29 cells are being 
stimulated into producing nitric oxide with different factors, rather than the IL-1, 
TNF-a and IFN-y.
The effect of the conditioned media could also be inhibited by pre-treating the 
HT-29 cells with IL-lra. The effect of the IL-lra was not seen when directly 
treating the MMCs with the IL-lra. This would suggest that IL-1 is one of the 
soluble factors secreted by the stimulated MMCs that are necessary to induce NO 
production in colonic epithelial cells.
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No data concerning the MMCs and HT-29 model with respect to the production of 
IL-8 has been presented as when LPS and IFN-y stimulate the MMCs, large 
quantities of IL-8 are released, thus rendering it impossible to examine the effect 
of either steroids or the “anti-inflammatory cytokines” on the HT-29 cells.
Despite steroids being used in the treatment of inflammatory bowel disease since 
the 1950s there is still a lack of understanding of how exactly steroids work. 
There is a large amount of published data looking at the actions of steroids, 
showing that they have a wide variety of actions. Glucocorticoid hormones are 
effective in controlling inflammation, but the mechanisms that confer this action 
are largely unknown. The genes whose activities are modulated in the anti­
inflammatory process code for important components of the inflammatory process 
such as cytokines, adhesion molecules and enzymes. Most of them do not carry a 
classical binding site for regulation by a glucocorticoid receptor, but have instead 
regulatory sequence for transcription factors such as NF-kappa B. It is thought 
that steroids may inhibit NF-kappa B transcription factor (Barnes and Adcock, 
1993; Cato and Wade, 1996) The exact cellular site of action is unknown. If this 
could be determined then it is possible that new therapies could be designed that 
are designed to act on a particular cell or cell type perhaps thus enabling control of 
these chronic diseases without subjecting the patient to the high risk of side 
effects of steroids. Despite extensive investigation of newer therapies such as 
IL-10 and an understanding of some of its actions, there is still a large amount 
unknown both about its mechanism, and possibly more importantly, its site of 
action.
Again, the exact role of nitric oxide in the chronic inflammatory response of 
inflammatory bowel disease is unknown, yet it would appear to be important, 
probably when produced in excess by iNOS. It is known that the colonic epithelial 
cell is essential for the production of NO in any colonic inflammation, and this 
research would suggest that it is necessary for other cell types to be present; i.e. 
mixed mononuclear cells. This may allow more specific targeting of therapeutic 
agents to reduce NO production and thus inflammation in IBD.
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Conclusions
There does appear to be significant differences between the behaviour of the 
HT-29 cell line model and the colonic epithelial cell in the biopsy model. How 
much of this is due to differences between an epithelial cell from a cell line and 
the in vivo colonic epithelial cell or to how the epithelial cell line is stimulated in 
models is still unclear. However, it is likely that a large part of this difference is 
due to the influence of surrounding cells.
Expression of iNOS in colonic epithelial cells does seem to be sensitive to 
therapeutic doses of both prednisolone and budesonide, but that these drugs do not 
appear to act directly upon the epithelial cell itself but upon cells in the 
surrounding tissues. Any difference found in IBD, is likely to be due to the 
intraepithelial lymphocytes and other mixed mononuclear cells present in 
inflamed colonic mucosa.
IL-10, as well as IL-4 and to a lesser extent IL-13, has a powerful effect on 
colonic epithelial cell as measured by iNOS expression in the biopsy model of 
IBD in contrast to cell line work published earlier. Again this difference between 
the two models is likely to be due to an effect of IL-10 on surrounding cells, 
primarily mixed mononuclear cells.
These surrounding white cells stimulate nitric oxide production by the production 
of soluble factors, and that one of these factors is almost certainly IL-1, as 
demonstrated by the ability of IL-lra to partially inhibit this production.
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